

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX001	SOLVAY 068788	SOLVAY 068841	8/11/1995	Supply Agreement	Bua 05 (8/23/2011); Dudley 08 (6/17/2011); Govt Ex. 1008 (Supply Agreement FTC-955-00002273-2296)
DX002	SOLVAY 068792	SOLVAY 068815	8/11/1995	License Agreement between Unimed Pharmaceuticals, Inc. and Laboratories Besins Iscovesco S.A.	Kottayil 07 (6/29/2011)
DX003	UCLA 007012	UCLA 007044	4/1/1997	Revised Protocol UMD-96-017	
DX004	UPI 006812	UPI 007111		NDA 21-015, Chemistry, Manufacturing, and Controls	
DX005	UPI 027860	UPI 028012	9/9/1999	Four-Month Safety Update	
DX006	UPI 063076	UPI 063113	12/14/1996	Clinical Trial Agreement, UMD-96-017 including appendices	
DX007	UPI 063127	UPI 063162	4/12/1996	Clinical Trial Agreement, UMD-96-012 including appendices (Protocol UMD-96-012)	
DX008				AndroGel 1% Label	
DX009				FDA Summary Review, NDA 022219	Mann 03 (2/8/2017)
DX010				FDA Medical Review, NDA 204399	Mann 06 (2/8/2017)
DX011				FDA Summary Review, NDA 205488	Mann 09 (2/8/2017)
DX012				Memorandum Opinion, <i>Unimed Pharmaceuticals LLC v. Perrigo Co</i> , No. 13-cv-236 (D. Del. Mar. 11, 2015)	
DX013				Thomas, <i>Pharmaceutical Patent Law</i> ch. 7.1 (3d ed. 2015)	
DX014				Complaint, <i>Unimed Pharmaceuticals LLC v. Lupin Atlantis Holdings SA</i> , No. 15-cv-904 (D. Del. Oct. 9, 2015)	
DX015				Complaint, <i>Unimed Pharmaceuticals LLC v. Amneal Pharmaceuticals LLC</i> , No. 15-cv-964 (D. Del. Oct. 23, 2015)	
DX016				Complaint, <i>Unimed Pharmaceuticals LLC v. Sandoz Inc.</i> , No. 15-cv-1120 (D. Del. Dec. 3, 2015)	
DX017				Complaint, <i>Unimed Pharmaceuticals LLC v. Dr. Reddy's Laboratories Ltd.</i> , No. 15-cv-1142 (D. Del. Dec. 10, 2015)	
DX018				Complaint, <i>Unimed Pharmaceuticals LLC v. TWI Pharmaceuticals, Inc.</i> , No. 16-cv-810 (D. Del. Sept. 16, 2016)	
DX019				Lynde, <i>Moisturizers: What They Are and How They Work</i> , Skin Therapy Letter, Dec. 2001 [MDL Dkt. 620-8]	
DX020				Blank, <i>Factors Which Influence the Water Content of the Stratum Corneum</i> , 18 J. Investigative Dermatology 460 (1952) [MDL Dkt. 620-9]	
DX021				Docket Sheet, <i>Unimed Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc.</i> , No. 03-cv-2501 (N.D. Ga.)	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX022				Docket Sheet, <i>Unimed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc.</i> , No. 03-cv-2503 (N.D. Ga.)	
DX023	AGEL MDL 002-000945	AGEL MDL 002-000993	8/11/2004	Watson's Response to Unimed's First Set of Requests for Admission Nos. 1-147	
DX024	AGEL MDL 002-000257	AGEL MDL 002-000308	8/16/2004	Paddock's Responses to Unimed's First Set of Requests for Admission Nos. 1-146	
DX025			1/19/2016	Direct Purchaser Class Plaintiffs' Response to Defendant AbbVie Products LLC's Fourth Set of Interrogatories to Private Plaintiffs	
DX026			5/4/2015	Plaintiff FTC's Responses to Defendant AbbVie Products LLC's First Set of Interrogatories to All Plaintiffs	
DX027			1/19/2016	Plaintiff FTC's Responses to Defendant AbbVie Products LLC's Fifth Set of Interrogatories to Plaintiff FTC	
DX028			3/25/2016	Plaintiff FTC's First Supplemental Response to Defendant Actavis, Inc.'s First Set of Interrogatories to Plaintiff FTC [Nos. 1-2]	
DX029			4/21/2016	Plaintiff FTC's Second Supplemental Responses to Defendant Actavis, Inc.'s First Set of Interrogatories to Plaintiff FTC [Nos. 1-2]	
DX030			9/8/2016	Plaintiff FTC's First Supplemental Responses to Defendant AbbVie Products LLC's First Set of Interrogatories to All Plaintiffs [Nos. 11-14 and Original Responses Nos. 1-16]	
DX031			9/8/2016	Plaintiff FTC's First Supplemental Response to Defendant AbbVie Products LLC's Second Set of Interrogatories to All Plaintiffs [No. 17]	
DX032			9/8/2016	Plaintiff FTC's First Supplemental Responses to Defendant AbbVie Products LLC's Third Set of Interrogatories to All Plaintiffs [No. 18]	
DX033			9/8/2016	Plaintiff FTC's Third Supplemental Responses to Defendant Actavis, Inc.'s First Set of Interrogatories to Plaintiff FTC [Nos. 1-2]	
DX034			9/8/2016	Plaintiff FTC's First Supplemental Responses to Defendants' First Set of Interrogatories [Nos. 1-2]	
DX035	AGEL MDL 001-010777	AGEL MDL 001-010787		CV of Robert E. Dudley, Ph.D.	Dudley 01 (3/21/2005)
DX036			00/00/1995	Bhasin, et al., "Clinical Practice Guidelines - Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline" (1995)	Hayes 10 (6/30/2017); Hayes 02 (11/18/2016)
DX037			06/00/2010	Bhasin, et al., "Clinical Practice Guidelines - Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline" (June 2010)	Hayes 03 (11/18/2016)
DX038	BESUS000017	BESUS000049	00/00/1995	Supply Agreement between Unimed Pharmaceuticals, Inc. and Laboratories Besins Iscovesco S.A.	Dale 01 (5/11/2016); Govt Ex. 1005; Bruno 03 (10/25/2016)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX039	AGEL MDL 002-007324	AGEL MDL 002-007382	12/00/1999	PowerPoint entitled Androgel Launch Plan Executive Summary	Hynd 04 (8/18/2011)
DX040	SOLVAY 017730	SOLVAY 017751	8/11/1995	Supply Agreement between Unimed Pharmaceuticals, Inc. and Laboratories Besins Iscovesco S.A.	
DX041	AGEL MDL 001-009800	AGEL MDL 001-009814	5/15/1996	Document entitled Investigator's Brochure Transdermal Testosterone (T) (1.0% T Hydroalcoholic Gel) for Androgen Replacement Therapy	Dobs 04 (8/13/2004)
DX042	AGEL MDL 001-009815	AGEL MDL 001-009839	12/3/1996	Document entitled A Phase II/III Evaluation of the Safety and Efficacy of Testosterone-Gel for Hormonal Replacement in Hypogonadal Men	Dobs 05 (8/13/2004)
DX043	BESFR 007248	BESFR 007270	1/4/1999	Note from Anne-Marie Catherine to Jean-Claude de Roquemaurel entitled Unimed attaching Supply Agreement between Unimed and Besins from Jay Bua	
DX044	UPIED0023864	UPIED0023865	3/3/1999	Email from Marcy Vella to Michele Alm	Knocke 09 (8/19/2011)
DX045	SOLVAY 108136	SOLVAY 108137	8/14/1999	Memorandum from Kate Robertson to Dave Knocke	Knocke 08 (8/19/2011)
DX046	AGEL MDL 001-012163	AGEL MDL 001-012164	12/13/2000	Memorandum (internal Paddock) from Teresa Surrell to Joann Zilka re Testosterone Gel Status Report	Erstad 05 (2/8/2008)
DX047	WTN0394827	WTN0394827	7/19/2001	Abbott/Watson JCC Meeting	
DX048	AGEL-MDL-016-000129	AGEL-MDL-016-000131	9/4/2002	Letter from TAP Pharmaceutical Products, Inc. to Solvay Pharmaceuticals, Inc. (Jim Hynd)	Shlevin 07 (5/29/2015)
DX049	SOLVAY-ED-0070093	SOLVAY-ED-0070106	03/00/2003	Document entitled Strategic Product Guidelines (AndroGel)	
DX050	SOLVAY 066461	SOLVAY 066462	1/6/2003	Letter from TAP Pharmaceutical Products, Inc. to Solvay Pharmaceuticals, Inc.	Shlevin 06 (5/29/2015)
DX051	WTN0223739	WTN0224253	1/7/2003	U.S. Patent no. 6503894	
DX052	PAR 045040	PAR 045793	1/7/2003	File History For U.S. Patent No. 6,503,894	Mahoney 11 (5/10/2016)
DX053	AGEL MDL 001-027032	AGEL MDL 001-027096	1/9/2003	Letter from Unimed to Paddock Labs Regarding Unimed Announces Receipt of Patent on Androgel	Zeleny 17 (2/9/2005)
DX054	PAR011348	PAR011349	1/13/2003	Email from Mary Beth Erstad to Bruce Paddock, et al.	
DX055	AGEL MDL 001-012184	AGEL MDL 001-012189	1/14/2003	Email chain among Mary Beth Erstad and other Paddock employees re: '894 patent	Erstad 14 (2/8/2008)
DX056	AGEL MDL 002-007895	AGEL MDL 002-007899	7/3/2003	FDA Not Approvable Letter, NDA 21463	
DX057	AGEL-MDL-008-017647	AGEL-MDL-008-017678	10/22/2003	Email from Jim Hynd to William Barnett (with attachment)	Hynd 33 (4/7/2016); Yang 08 (6/10/2015)
DX058	SLV367786	SLV367786	6/17/2004	Email from Jean-Louis Anspach to Harold Shlevin, Jim Hynd, et al.	
DX059	SLV367787	SLV367791	6/17/2004	JSC Meeting Minutes (Besins/Solvay) for May 27, 2004 meeting	
DX060	SLV368018	SLV368023	6/25/2004	Email from Jean-Louis Anspach to Roger De Neve, et al. (with attachment)	Hynd 31 (4/7/2016); Dale 04 (5/11/2016); Govt Ex. 188
DX061	AGEL-MDL-022-002630	AGEL-MDL-022-002630	6/28/2004	Email from Harold Shlevin to Dana Bolin	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX062	AGEL-MDL-022-002640	AGEL-MDL-022-002644	6/28/2004	JSC Meeting Minutes (Besins/Solvay) for June 17, 2004 meeting	
DX063	AGEL-MDL-022-002182	AGEL-MDL-022-002182	6/30/2004	Email from Roger De Neve to Jean-Louis Anspach, et al.	
DX064	AGEL-MDL-022-002187	AGEL-MDL-022-002182	6/30/2004	Document entitled Backup Manufacturing Site for TGel.doc, attachment to Email from Roger De Neve to Jean-Louis Anspach, et al.	
DX065	BNS0004083	BNS0004089	6/30/2004	Email from Christine Remant to Harold Shlevin, et al.	Bua 12 (4/20/2016)
DX066	SLV585168	SLV585174	6/30/2004	Email from Roger De Neve to Harold Shlevin, et al. (with attachments)	Mink 32 (10/2/2015); Lindsey 03 (3/30/2017); Bruno 05 (10/25/2016)
DX067	AGEL MDL 001-009722	AGEL MDL 001-009783	6/30/2004	Deposition Subpoena to Johns Hopkins University School of Medicine issued in <i>Unimed Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc.</i> No. 1:03-CV-2501-TWT	Dobs 02 (8/13/2004)
DX068	SLV054155	SLV054197	10/28/2004	PowerPoint entitled AndroGel (testosterone gel) 1% CIII Overview	
DX069	AGEL MDL 001-011736	AGEL MDL 001-011746	11/17/2004	Notice of 30(b)(6) Deposition of Watson Pharmaceuticals, Inc.	Ebert 01 (3/2/2005)
DX070	AGELMDL012012775	AGELMDL012012776	11/28/2004	Email from Harold Shlevin to Jim Hynd, et al.	
DX071	AGELMDL012000834	AGELMDL012000866	07/00/2005	PowerPoint entitled US Commercial Update	
DX072	AGELMDL012001852	AGELMDL012001894	07/00/2005	PowerPoint entitled US Commercial Update	Engert 01 (3/4/2016)
DX073	AGELMDL014014750	AGELMDL014014805	10/00/2005	PowerPoint entitled Board of Directors Meeting and Business Review (version 1)	
DX074	AGELMDL014014995	AGELMDL014015065	10/00/2005	PowerPoint entitled Board of Directors Meeting and Business Review (version 2)	
DX075	ICOS0000001	ICOS0000020	1/28/2005	Co-Promotion Agreement between Solvay Pharmaceuticals, Inc. and ICOS Technology Services, LLC	Blum 3 (12/11/2015)
DX076	AGEL-MDL-008-019243	AGEL-MDL-008-019265	2/17/2005	Email from Kevin Rose to Jean-Louis Anspach, et al.	Blum 19 (12/11/2015)
DX077	SLV195650	SLV195650	2/17/2005	Email from Jim Adelizzi to Elaine Yang, Jay Janco, et al.	
DX078	SLV195651	SLV195657	2/17/2005	PowerPoint entitled Solvay Pharmaceuticals, Inc. Specialty Products Sales Force Strategy PC/SMK Sales Impact Analysis (ZS Associates)	
DX079	SLV225843 A	SLV225843 A	7/5/2005	Email from Jean-Louis Anspach to Kevin Rose, et al. [Alt Bates SLV225843 redacted version]	
DX080	SLV225844	SLV225857	7/5/2005	PowerPoint entitled Business Review 2005-2009 Plan, attachment to Email from Jean-Louis Anspach to Kevin Rose, et al. (SLV225843 A and SLV225843)	Govt Ex. 0015
DX081	AGELMDL012001851	AGELMDL012001894	7/20/2005	Email from Brian Mitchell to Jim Hynd	Hynd 24 (4/7/2016)
DX082	AGELMDL013029197	AGELMDL013029198	7/25/2005	Email from Jay Janco to Vivek Mehta	
DX083	AGEL-MDL-022-004370	AGEL-MDL-022-004404	7/27/2005	Email from Harold Shlevin to Oliver Engert (with attachment)	Engert 09 (3/4/2016)
DX084	AGEL-MDL-014-034470	AGEL-MDL-014-034565	8/24/2005	PowerPoint entitled Business Review 2006-2010 Plan Version 3	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX085	AGEL-MDL-022-004612	AGEL-MDL-022-004612	9/15/2005	Email from Mark Hastings to Jim Hynd, et al.	
DX086	AGEL-MDL-022-004613	AGEL-MDL-022-004680	9/2/2005	PowerPoint entitled Polaris Accelerating Commercial Effectiveness Initiative 1a: Local Portfolio Assessment US Steering Committee Meeting	
DX087	WTN0086488	WTN0086488	9/9/2005	Email from E. Heimers to L. Amato, E. Tykot, T. Callahan, C. Ebert, and R. Furdyna re: Strategic Plan - From Blue Puddles to Oceans and attaching presentation Strategic Plan 2006	
DX088	WTN0086489	WTN0086530	9/9/2005	Presentation Strategic Plan 2006	
DX089	WTN0086531	WTN0086532	9/14/2005	Email from E. Tykot to E. Heimers, C. Ebert, L. Amato, R. Furdyna, and T. Callahan re: Strategic Plan - From Blue Puddles to Oceans attaching Watson Brand Strategy presentation	
DX090	WTN0086533	WTN0086551	9/14/2005	Watson Brand Strategy presentation.	
DX091	BNS0004390	BNS0004389	9/26/2005	Letter from Harold Shlevin to Roger de Neve	Bruno 06 (10/25/2016)
DX092	WTN0086760	WTN0086760	9/28/2005	Email from E. Heimers to A. Chao, C. Slacik, D. Buchen, L. Amato, C. Ebert, and C. Guzallis re: Preliminary Strategic Plan Meeting attaching presentation STRATEGIC PLAN FINAL.	
DX093	WTN0086761	WTN0086792	9/28/2005	STRATEGIC PLAN FINAL presentation.	
DX094	SLV190691 A	SLV190692 A	10/6/2005	Email from Rakowski, Susan to Anspach, Jean-Louis, et al.	Hynd 26 (4/7/2016)
DX095	WTN0087214	WTN0087214	10/11/2005	Email from E. Heimers to A. Chao, D. Buchen, and C. Slacik re: DRAFT Board Presentation attaching Watson Board 24Oct05 presentation.	
DX096	WTN0087215	WTN0087241	10/11/2005	Watson Board 24Oct05 presentation.	
DX097	SLV000240	SLV000300	10/14/2005	PowerPoint entitled 2006 Specialized Markets & Primary Care Business Plan	
DX098	WTN0087483	WTN0087483	10/21/2005	Email from E. Heimers to U. Soltys attaching presentation Watson Board OCT24 DRAFT	
DX099	WTN0087484	WTN0087514	10/24/2005	Watson Board OCT24 DRAFT	
DX100	ICOS0000021	ICOS0000021	10/24/2005	Letter from Solvay Pharmaceuticals to ICOS Corporation re Co-Promotion Agreement	Blum 04 (12/11/2015); Hynd 13 (4/6/2016)
DX101	WTN0087576	WTN0087604	10/24/2005	PowerPoint entitled Watson Brand Division Strategic Analysis & Options	
DX102	PAR458757	PAR458773	10/26/2005	Agreement between Par Pharmaceuticals, Inc. and Valeant Pharmaceuticals, North America	MacPhee 34 (3/18/2016); Reed 17 (11/16/2016); Tupman 14 (9/15/2016)
DX103	WTN0087635	WTN0087635	10/31/2005	Email from E. Heimers to A. Chao re: 1 on 1 Materials attaching SanofiAventis Discussion Guide 31OCT05 presentation.	
DX104	WTN0087636	WTN0087636	10/31/2005	SanofiAventis Discussion Guide 31OCT05 presentation.	
DX105	FTC-ICOS00286332	FTC-ICOS00286333	11/4/2005	Email from Gregory Geddes to William Mason	Blum 14 (12/11/2015)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX106	SLV429342	SLV429344	12/5/2005	Email from Jean-Louis Anspach	
DX107	SLV434564	SLV434567	12/5/2005	Email from Lynn Dale to Tom Elder, et al.	
DX108	SLV225626	SLV225628	12/5/2005	Email from Jean-Louis Anspach to Tom Elder, et al.	Bruno 07 (10/25/2016); Lindsey 02 (7/30/2018)
DX109	SLV432596	SLV432598	12/5/2005	Email from Tom Elder to Lynn Dale, et al.	Dale 02 (5/11/2016)
DX110	SLV447891	SLV447897	00/00/2006	Notes re 2006 Meetings	McIlvaine 12 (9/27/2016); McKelvie 49 (4/19/2017)
DX111	SLV447905 A	SLV447918	00/00/2006	Notes re 2006 Meetings	McKelvie 50 (4/19/2017)
DX112			01/00/2006	PowerPoint entitled Contingency Plan (January 2006)	Hynd 15 (4/6/2016)
DX113	AGEL-MDL-012-004927	AGEL-MDL-012-004971	10/00/2006	PowerPoint entitled Board of Directors Meeting and Business Review	Lipinski 11 (5/19/2016); Edwards17 (5/28/2015)
DX114	ABBVIE-AGEL00518934	ABBVIE-AGEL00518954	04/00/2006	PowerPoint entitled Sales Strategy (Watson JCC Meeting) (April 2006)	Krull 04 (11/18/2015)
DX115	SLV455625	SLV455636	1/10/2006	Email from Murray Kay to Jim Hynd (with attachment)	Kay 28 (6/9/2011); Hynd 16 (8/18/2011); Downey 01 (5/8/2015); Govt Ex. 164; Hynd 03 (4/6/2016)
DX116	SLV451648	SLV451648	1/27/2006	Email from Lisa Helm to Andre Benirschke	
DX117	SLV451649 A	SLV451652 A	1/27/2006	Document entitled Management Discussion & Analysis (December 2005), attachment to Email from Lisa Helm to Andre Benirschke (SLV451648)	
DX118	SLV451649	SLV451652	1/27/2006	Document entitled Management Discussion & Analysis (December 2005), attachment to Email from Lisa Helm to Andre Benirschke (SLV451648)	Hynd 27 (4/7/2016)
DX119	WTN0090108	WTN0090122	1/28/2006	Brand Board Final 30JAN05 presentation	
DX120	WTN0090107	WTN0090107	1/30/2006	Email from E. Heimers to U. Soltys re: Board Presentation attaching Brand Board Final 30JAN05 presentation.	
DX121	WTN0038959	WTN0038960	1/31/2006	Email from Patty Eisenhour to Amy Hulina, et al.	
DX122	SLV449028	SLV449079	2/3/2006	PowerPoint entitled Marietta Employee Forum	
DX123	WTN0090134	WTN0090134	2/7/2006	Email from L. Amato to E. Heimers re: 2/7 Agenda & Follow up Actions attaching Top 5 Goals - Brand Sales & Marketing presentation	
DX124	WTN0090165	WTN0090169	2/7/2006	Top 5 Goals - Brand Sales & Marketing presentation	
DX125	SLV582856	SLV582872	2/7/2006	PowerPoint entitled PLT Meeting	
DX126	SLV583924	SLV583926	3/13/2006	Email from James Ferguson to Peter Edwards	Edwards 03 (5/28/2015)
DX127	HN ANG 00136851	HN ANG 00136863	3/17/2006	Document entitled IPD Analytics Pharmaceutical Patent Litigation Monitor re Androgel: Unimed Appears to Have Advantage Despite Flaws in Patent	
DX128	SLV511170	SLV511170	4/6/2006	Email from Laurie Downey to Murray Kay, et al.	Downey 05 (5/8/2015); Yang17 (6/10/2015); Cautreels 08 (10/23/2015); Govt Ex. 0208

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX129	WTN0313265	WTN0313271	4/13/2006	Document entitled Watson Pharmaceuticals, Inc. R&D Monthly Update Meeting	Leffler 18 (11/8/2016)
DX130	WTN0330936	WTN0330936	4/17/2006	Email from D. Buchen to D. Budillo re: Conf Call	
DX131	WTN0039363	WTN0039364	4/18/2006	Email from D. Buchen to D. Budilo re: Contact Information.	
DX132	WTN0330931	WTN0330931	4/18/2006	Email from D. Budilo to D. Buchen re: Meeting 4/20/06	
DX133	WTN0330937	WTN0330937	4/18/2006	Email from D. Buchen to P. Edwards re: URGENT: Meeting Details	
DX134	WTN0288356	WTN0288373	4/19/2006	Email from E. Heimers to D. Buchen and E. Tykot with attached Unimed AndroGel FINAL slides.	Heimers 2 (3/21/2016); Buchen 14 (7/8/2011); Tykot 5 (7/15/2011); Govt Ex. 2031; WTN0093300-WTN0093316
DX135	WPI-E-1512249	WPI-E-1512265	4/19/2006	Email from Ed Heimers to David Buchen and Ed Tykot (with attachments)	Heimers 02 (3/21/2016); Reed 25 (7/12/2017)
DX136	WTN0330932	WTN0330933	4/25/2006	Email from D. Budilo to D. Buchen re: Meeting arrangements for Thursday, 4/27/06.	
DX137	SLV075107	SLV075116	4/25/2006	tulip.mdb	Janco 36 (10/22/2015)
DX138	SLV084760	SLV084769	4/26/2006	tulip2.mdb	Janco 37 (10/22/2015)
DX139	SLV094475	SLV094484	4/27/2006	tulip3.mdb	Janco 38 (10/22/2015)
DX140	WTN0288577	WTN0288584	4/28/2006	Email from E. Tykot to E. Heimers re: Summary of Terms attaching Watson Terms presentation.	Buchen 17 (7/8/2011)
DX141	PAR267551	PAR267551	5/1/2006	Email from Scott Tarriff to Ronald M. Nordmann	
DX142	WTN0093325	WTN0093325	5/2/2006	Email from E. Heimers to D. Buchen and E. Tykot re: TRT market by Urology breakdown attaching eh-trturo spreadsheet.	
DX143	PAR267553	PAR267553	5/8/2006	Email from Scott Tarriff to Carol Malagoli	
DX144	SLV409436	SLV409630	5/11/2006	Email from Jay Janco to Ed Tykot, et al. (with attachments)	Janco 34 (10/22/2015)
DX145	WTN0103779	WTN0103781	5/12/2006	Email from A. Pereira to D. Kalwani re: Solvay Urology Target List 051106.	
DX146	WPI-E-1509744	WPI-E-1509745	5/12/2006	Email from E. Tykot to E. Heimers and D. Buchen re: Solvay Urology Target List 051106.	Heimers 14 (3/21/2016)
DX147	SLV456807 A	SLV456807 A	5/22/2006	Email from Jean-Louis Anspach to Jim Hynd	Govt Ex. 0248
DX148	WTN0104087	WTN0104088	5/23/2006	Email from A. Pereira to T. Guo re: Solvay and Green Team Target Analysis	
DX149	WTN0104089	WTN0104090	5/23/2006	Email from A. Pereira to T. Guo re: Solvay and Green Team Target Analysis.	
DX150	SLV546933	SLV546933	5/23/2006	Email from Praveen Nadella to Jean-Louis Anspach, et al.	
DX151	SLV546934	SLV546956	5/23/2006	PowerPoint entitled AndroGel Accelerations: Brainstorm Sessions for Disease Awareness / Perception and Compliant Persistence, attachment to SLV546933	
DX152	WTN0099534	WTN0099534	5/24/2006	Email from T. Guo to A. Pereira, D. Kalwani, and S. Renna re: Solvay and Green Team Target Analysis.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX153	WTN0099535	WTN0099535	5/24/2006	OAB Decile Breaksown for Green/Solvay Overlapped Physicians	
DX154	WTN0099536	WTN0099536	5/24/2006	Target Count Breakdown of Solvay Target List	
DX155	WTN0103690	WTN0103691	5/24/2006	Email from E. Tykot to A. Pereira re: Solvay and Green Team Target Analysis	
DX156	WTN0104091	WTN0104092	5/24/2006	Email from A. Pereira to E. Tykot re: Solvay and Green Team Target Analysis	
DX157	WTN0004569	WTN0004569	5/26/2006	Email from L. Amato to E. Tykot.	
DX158	WTN0103692	WTN0103692	5/30/2006	Email from E. Tykot to S. Renna re: Data request.	
DX159	WTN0103749	WTN0103749	5/30/2006	Email from D. Kalwani to A. Pereira re: Solvay Analysis - Additional Information Needed	
DX160	WTN0104093	WTN0104093	5/30/2006	Email from A. Pereira to L. Amato re: Solvay Analysis	
DX161	WTN0330840	WTN0330841	5/30/2006	Email from L. Amato to R. Furdyna re: Solvay Analysis	
DX162	WTN0330842	WTN0330844	5/31/2006	Email from L. Amato to R. Furdyna re: Solvay analysis.	
DX163	SLV407956	SLV407956	9/27/2006	Email from Jay Janco to Mark Hastings	
DX164	SLV407957	SLV407958	6/1/2006	PowerPoint entitled Watson AndroGel Urology Coverage	
DX165	WPI-E-1509746	WPI-E-1509747	6/2/2006	Email from E. Tykot to E. Heimers and L. Amato re: Additional Information Requested.	Heimers 22 (3/21/2016)
DX166	WTN0005271	WTN0005271	6/2/2006	Email from A. Pereira to E. Tykot and L. Amato re: Additional Information Requested.	Amato 15 (8/26/2015)
DX167	WPI-E-1509748	WPI-E-1509750	6/8/2006	Email from E. Heimers to E. Tykot and L. Amato re: Co-Promotion Agreement.	Heimers 10 (3/21/2016)
DX168	SLV503328	SLV503330	6/14/2006	Email from Jay Janco to Brian Mitchell and Jim Hynd (with attachment)	Elhauge 07; Tupman 23; Orne 05
DX169	SLV526105	SLV526140	6/30/2006	PowerPoint entitled AndroGel Acceleration Team Update	
DX170	WTN0004570	WTN0004571	7/12/2006	Email from L. Amato to G. Frederick re: Co-Promotion Agreement.	
DX171	WTN0093457	WTN0093458	7/12/2006	Email from E. Tykot to L. Amato and S. Salvucci re: Co-Promotion Agreement.	
DX172	SLV531226	SLV531240	7/12/2006	Email from Lisa Helin to Jean-Louis Anspach (with attachment)	Govt Ex. 0250 (5/6/2008 Anspach)
DX173	SLV003224	SLV003239	7/17/2006	PowerPoint entitled AndroGel Marketing Presentation	Govt Ex. 0177 (3/12/2008 Kay)
DX174	WTN0004596	WTN0004598	7/18/2006	Email from L. Amato to G. Frederick re: Co-Promotion Agreement.	
DX175	WTN0099542	WTN0099543	7/24/2006	Email from S. Renna to S. Steinkopf re: Physician Deciles.	
DX176	WTN0093601	WTN0093601	7/31/2006	Email from E. Heimers to C. Ebert and J. Gardner re: SLC Presentations attaching SLC Senior Staff Update 2Aug06 presentation.	
DX177	WTN0093602	WTN0093624	7/31/2006	SLC Senior Staff Update 2Aug06 presentation	
DX178	WTN0105935	WTN0105935	8/7/2006	Email from B. Mitchell to E. Tykot re: Headcount.	
DX179	WTN0106019	WTN0106020	8/7/2006	Email from L. Amato to E. Tykot re: headcount.	
DX180	WTN0106250	WTN0106251	8/7/2006	Email from E. Tykot to L. Amato re: Headcount.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX181	WTN0106254	WTN0106255	8/7/2006	Email from E. Tykot to B. Mitchell re: Headcount.	
DX182	SLV510554	SLV510555	9/5/2006	Email from Paul Campanelli to Peter Edwards, et al.	Hynd 07 (4/6/2016)
DX183	WTN0007010	WTN0007026	9/7/2006	Sales Incentive Review Committee (SIRC) presentation	
DX184	WTN0093689	WTN0093690	9/11/2006	Email from E. Heimers to P. Shunning, U. Soltys, L. Amato, and D. Miranda re: Watson Fall 2006 PPM General Session Presenter Slide Decks attaching PPM Dallas 2006 GREEN GOLD presentation.	
DX185	WTN0093691	WTN0093708	9/11/2006	PPM Dallas 2006 GREEN GOLD presentation.	
DX186	N/A	N/A	9/13/2006	Final Settlement and Release Agreement between Unimed Pharmaceuticals, Inc., Laboratories Besins Iscovesco, and Watson Pharmaceuticals, Inc.	Buchen 25 (5/5/2015); Downey 18 (5/8/2015)
DX187	WPI-E-0900021	WPI-E-0900044	9/13/2006	Co-Promotion Agreement between Solvay Pharmaceuticals, Inc., Unimed Pharmaceuticals, Inc., and Watson Pharma, Inc.	Buchen 26 (2015); Buchen 18 (2011); Kay 18 (2011); Govt Ex. 2001-C; WTN0286982-WTN0287004
DX188			9/13/2006	Final Settlement and Release Agreement between Unimed Pharmaceuticals, Inc., Laboratories Besins Iscovesco, and Watson Pharmaceuticals, Inc.	Downey 18 (5/8/2015); Buchen 25 (5/5/2015)
DX189	FTC-955-00005038	FTC-955-00005076	9/13/2006	Final Settlement and Release Agreement and Patent License Agreement between Unimed Pharmaceuticals, Laboratories Besins Iscovesco, Par Pharmaceuticals Cos., Inc., and Paddock Laboratories, Inc.	Downey 20 (5/8/2015); Govt Ex. 0043-B [PADD018272-18286]
DX190	FTC-955-00005115	FTC-955-00005140	9/13/2006	Co-Promotion Agreement between Solvay Pharmaceuticals, Inc., Unimed Pharmaceuticals, Inc., and Par Pharmaceutical Cos., Inc.	Downey 22 (5/8/2015)
DX191	WTN0286953	WTN0286969	9/13/2006	Final Settlement and Release Agreement between Unimed Pharmaceuticals, Laboratories Besins Iscovesco, and Watson Pharmaceuticals, Inc.	Buchen 20 (7/8/2011); Kay 20 (6/9/2011); Govt Exh. 2001-A
DX192	WTN0286970	WTN0286981	9/13/2006	Patent License Agreement between Unimed Pharmaceuticals, Laboratories Besins Iscovesco, and Watson Pharmaceuticals, Inc.	Buchen 21 (7/8/2011); Kay 19 (6/9/2011); Govt Ex. 2001-B
DX193	PADD014645	PADD014682	9/13/2006	Backup Manufacturing and Supply Agreement between Unimed Pharmaceuticals, Inc., Laboratories Besins International S.A., and Par Pharmaceutical Cos., Inc. [Alt Bates FTC-955-00005077-5114]	Dale 05 (5/11/2016); Downey 21 (5/8/2015)
DX194	PADD002209	PADD002212	9/13/2006	Letter from Par Pharmaceutical to Paddock Laboratories, Inc.	
DX195	AGEL-MDL-014-034022	AGEL-MDL-014-034028	9/14/2006	Email from Jim Hynd to Murray Kay and Brian Mitchell	
DX196	SLV474739	SLV474770	9/14/2006	Email from Jim Hynd to Laurie Downey, et al. (with attachment)	Hynd 28 (4/7/2016); Govt Ex. 0127
DX197	WTN0004630	WTN0004631	9/15/2006	Email from L. Amato to E. Tykot re: AndroGel training.	
DX198	WTN0004632	WTN0004633	9/15/2006	Email from L. Amato to G. Frederick re: AndroGel training.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX199	WTN0072914	WTN0072915	9/15/2006	Email from E. Tykot to G. Frederick re: AndroGel training.	
DX200	WTN0106022	WTN0106023	9/15/2006	Email from L. Amato to E. Tykot re: AndroGel training.	
DX201	WTN0106186	WTN0106186	9/15/2006	Email from T. Gerrits to E. Tykot re: AndroGel training.	
DX202	WTN0106312	WTN0106312	9/15/2006	Email from E. Tykot to L. Amato re: AndroGel training.	
DX203	WTN0106313	WTN0106314	9/15/2006	Email from E. Tykot to G. Frederick re: AndroGel training.	
DX204	SLV304325	SLV304326	9/15/2006	Email from Jim Hynd to Marty Comer, et al.	Hynd 30 (4/7/2016); Govt Ex. 0045
DX205	WTN0071197	WTN0071199	9/16/2006	Email from G. Frederick to E. Tykot and L. Amato re: AndroGel training	
DX206	WTN0071200	WTN0071201	9/18/2006	Email from G. Frederick to L. Amato re: AndroGel training	
DX207	WTN0106590	WTN0106591	9/18/2006	Email from E. Heimers to L. Amato re: JCC AndroGel	
DX208	WTN0071202	WTN0071202	9/19/2006	Email from G. Frederick to L. Amato re: AndroGel Training Proposal - Dates and Locations	
DX209	WTN0071203	WTN0071204	9/19/2006	Email from G. Frederick to L. Amato re: AndroGel Training Proposal - Dates and Locations	
DX210	WTN0105989	WTN0105989	9/19/2006	Email from B. Mitchell to E. Tykot re: Transition Meeting.	
DX211	WTN0105991	WTN0105994	9/20/2006	Email from B. Mitchell to E. Tykot re: Transition Meeting	
DX212	WTN0106320	WTN0106321	9/20/2006	Email from E. Tykot to B. Mitchell re: Transition Meeting	
DX213	WTN0071209	WTN0071209	9/21/2006	Email from G. Frederick to L. Amato re: AndroGel	
DX214	WTN0071206	WTN0071208	9/21/2006	Email from G. Frederick to L. Amato re: AndroGel training	
DX215	AGEL-MDL-008-006270	AGEL-MDL-008-006292	9/21/2006	Email from Jim Hynd to Rich Post, et al. (with attachment)	Hynd 24 (8/18/2011)
DX216	SLV582181	SLV582184	9/21/2006	Minutes of First Global Joint Steering Committee AndroGel September 21, 2006 meeting [draft]	Dale 03 (5/11/2016)
DX217	WTN0106331	WTN0106334	9/22/2006	Email from E. Tykot to B. Mitchell re: Transition Meeting	
DX218	SLV510866	SLV510867	9/25/2006	Email from Jim Hynd to Laurie Downey, et al.	
DX219	WTN0071215	WTN0071216	9/26/2006	Email from G. Frederick to R. Ferguson re: Welcome Letter	
DX220	WTN0072774	WTN0072774	9/26/2006	Email from R. Ferguson to F. Frederick re: Welcome Letter	
DX221	WTN0068045	WTN0068046	9/27/2006	Email from S. Renna to J. Cocuzza re: Green Team Sales Roster for Solvay	
DX222	WTN0070774	WTN0070777	9/27/2006	Email from J. Cocuzza to G. Frederick re: Green Team Sales Roster for Solvay - REVISED COPY.	
DX223	WTN0071217	WTN0071218	9/27/2006	Email from G. Frederick to S. Renna re: Watson Welcome Letter	
DX224	WTN0071220	WTN0071221	9/27/2006	Email from G. Frederick to R. Ferguson re: Welcome Letter	
DX225	WTN0072776	WTN0072778	9/27/2006	Email from R. Ferguson to G. Frederick re: Welcome Letter	
DX226	WTN0103639	WTN0103640	9/27/2006	Email from G. Frederick to S. Renna re: Welcome Letter	
DX227	WTN0105995	WTN0106000	9/27/2006	Email from B. Mitchell to E. Tykot re: Transition Meeting.	
DX228	WTN0106337	WTN0106342	9/27/2006	Email from E. Tykot to B. Mitchell re: Transition Meeting	
DX229	SLV477701	SLV477702	9/27/2006	Email from Thomas MacAllister to Flo Gilson, et al.	
DX230	AGEL-MDL-015-020773	AGEL-MDL-015-020773	9/28/2006	Email from Vincent Amyot to Jean-Louis Anspach, et al.	
DX231	AGEL-MDL-015-020774	AGEL-MDL-015-020775	9/28/2006	Meeting Minutes (Par/Solvay) for September 28, 2006 meeting	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX232	WTN0071222	WTN0071223	9/29/2006	Email from G. Frederick to R. Ferguson re: Welcome Letter	
DX233	WTN0072779	WTN0072781	9/29/2006	Email from R. Ferguson to G. Frederick re: Welcome Letter	
DX234	WTN0072782	WTN0072782	10/3/2006	Email from R. Ferguson to G. Frederick re: Conference Call.	
DX235	WTN0072783	WTN0072785	10/3/2006	Email from R. Ferguson to G. Frederick re: Conference Call	
DX236	WTN0072786	WTN0072789	10/5/2006	Email from R. Ferguson to T. Vaughan re: Conference Call	
DX237	WTN0072790	WTN0072793	10/5/2006	Email from R. Ferguson to G. Frederick re: Conference Call	
DX238	WTN0072796	WTN0072796	10/9/2006	Email from R. Ferguson to G. Frederick re: Home Study Training Outline attaching Androgel Home study agenda document.	
DX239	WTN0072797	WTN0072798	10/9/2006	Androgel Home study agenda document.	
DX240	WTN0005585	WTN0005638	10/12/2006	Presentation: Solvay/Watson Co-promote Discussion	Amato 04 (8/26/2015)
DX241	WTN0074223	WTN0074225	10/12/2006	Minutes of the Working Session - Watson & Solvay	
DX242	WTN0106832	WTN0106832	10/13/2006	Email from J. Johnson to R. Furdyna	
DX243	WTN0070598	WTN0070599	10/13/2006	Email from L. Amato to E. Heimers re: AndroGel Training	
DX244	WTN0106873	WTN0106873	10/17/2006	Email from J. Johnson to E. Heimers, L. Amato, R. Furdyna, C. Yeomans, R. Katzenback, and R. DeVivo re: 2007 Brand Forecast (Revised) attaching Brand Portfolio 2007v.1 spreadsheet.	
DX245	WTN0291967	WTN0291969	10/31/2006	Letter from E. Lenge to G. Buehler re: Documentation of Litigation/Settlement Outcome for ANDA No. 76-737 1% Testosterone Gel	Petrie 04 (3/16/2016)
DX246	WTN0072839	WTN0072839	11/6/2006	Email from R. Ferguson to G. Frederick re: Tentative Agenda attaching Watson Training Agenda document.	
DX247	WTN0072840	WTN0072841	11/6/2006	Watson Training Agenda document.	
DX248	AGEL-MDL-012-005926	AGEL-MDL-012-005926	11/13/2006	Email from Murray Kay to Jim Hynd and Laurie Downey	
DX249	AGEL-MDL-012-005927	AGEL-MDL-012-005927	11/13/2006	Spreadsheet entitled Risk Analysis.xls, attachment to Email from Murray Kay to Jim Hynd and Laurie Downey (AGEL-MDL-012-005926)	
DX250	AGEL-MDL-024-008690	AGEL-MDL-024-008694	11/17/2006	PowerPoint entitled AndroGel Urology Call Plan - Evaluation of the Watson Proposed Call Plan [Alt Bates SLV041185-41189]	
DX251	WTN0451547	WTN0451547	11/27/2006	AndroGel Co-Promotion Marketing Plan, AndroGel Brand Team, November 27, 2006	
DX252	PAR205188	PAR205191	11/27/2006	Email from Nefertiti Greene to Leslie Rhee	Greene 17 (9/2/2015); Reed 09 (11/16/2016)
DX253	WTN0287464	WTN0287473	11/29/2006	Email from V. Amyot to G. Ferguson, L. Amato, S. Zhu re: Minutes from the last JCC [Govt. Exhibit 2004]	Gov Ex 2004
DX254	AGEL-MDL-014-029600	AGEL-MDL-014-029600	12/13/2006	Email from Lisa Helin to Murray Kay	
DX255	AGEL-MDL-014-029601	AGEL-MDL-014-029602	12/13/2006	Document entitled Global P&L Results, attachment to Email from Lisa Helin to Murray Kay (AGEL-MDL-014-029600)	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX256	SLV041219	SLV041224	12/13/2006	PowerPoint entitled Watson Call Plan Designed Considerations, Results (ZS Associates)	
DX257	SLV515673	SLV515687	08/00/2007	PowerPoint entitled Solvay/Watson JCC Meeting	
DX258	AGEL-MDL-006-0009778	AGEL-MDL-006-0009792	08/00/2007	PowerPoint entitled Solvay/Watson JCC Meeting [Alt Bates SLV515673-515687]	
DX259	SLV446804	SLV446816	10/00/2007	Notes by Murray Kay re Board Notes	
DX260	AGEL-MDL-024-000785	AGEL-MDL-024-000786	1/24/2007	JCC Meeting Minutes (Par/Solvay) for January 17, 2007 meeting	
DX261	AGEL-MDL-013-046721	AGEL-MDL0013-046722	1/25/2007	Email from Frederick Waithe to Brian Mitchell (with attachment)	Janco 13 (8/23/2011)
DX262	WTN0287578	WTN0284582	1/26/2007	Spreadsheet 2006 Urology P&L	Gov Ex 2013
DX263	WTN0094809	WTN0094809	2/5/2007	Email from E. Tykot to E. Heimers re: BD 2006 Summary.	
DX264	WTN0094810	WTN0094814	2/5/2007	2006 BD Summary presentation.	
DX265	PADD023873	PADD023880	2/21/2007	Document entitled Solvay Pharmaceuticals, Inc. Supplier Audit Report of Paddock Laboratories	Dale 07 (5/11/2016); Maloney17 (7/14/2011); Downey25 (5/8/2015); Mink 05 (10/2/2015); Bruno 12 (10/25/2016)
DX266	AGEL-MDL-014-030906	AGEL-MDL-014-030906	2/22/2007	Email from Randy Allen to Laurie Downey, et al.	
DX267	AGEL-MDL-014-030927	AGEL-MDL-014-030936	4/18/2005	Document regarding Shutdown of manufacturing at the Main Street Facility in Baudette (Note SPh 2005/018)	
DX268	WTN0095695	WTN0095697	3/22/2007	BD Update 3.22.07 spreadsheet.	
DX269	WTN0095694	WTN0095694	3/23/2007	Email from E. Tykot to E. Heimers re: BD update attaching BD Update 3.22.07 spreadsheet.	
DX270	WTN0095820	WTN0095823	4/2/2007	Email from Ed Heimers to Allen Chao (with attachment)	Heimers 18 (3/21/2016)
DX271	WTN0361822	WTN0361822	4/12/2007	AndroGel JCC Meeting, Sales Operations Update	
DX272	SLV449312	SLV449313	4/18/2007	Email from Jean-Louis Anspach to Murray Kay, et al.	
DX273	SLV542464	SLV542466	4/18/2007	Email from Lynn Dale to Jean-Louis Anspach	Dale 06 (5/11/2016); Bruno 08 (10/25/2016)
DX274	SLV583437	SLV583439	5/23/2007	Email from Mzrebiec@parpharm.com to Blaurent@besins-healthcare.com, et al.	
DX275			5/23/2007	Letter from FDA to Par Pharmaceutical, Inc. re ANDA 76-744	Dale 12 (5/11/2016)
DX276	AGEL-MDL-009-005637	AGEL-MDL-009-005637	5/11/2007	Email from Lynn Dale to Mke Dornhecker	
DX277	AGEL-MDL-009-005638	AGEL-MDL-009-005642	6/5/2007	PowerPoint entitled AndroGel Manufacturing Update	
DX278	SLV462696	SLV462696	6/8/2007	Email from Jean-Louis Anspach to Murray Kay, Jim Hynd, et al.	
DX279	SLV462697	SLV462701	6/5/2007	PowerPoint entitled AndroGel Manufacturing Update	
DX280	AGEL-MDL-009-005017	AGEL-MDL-009-005017	11/15/2007	Email from Murray Kay to Lynn Dale	
DX281	AGEL-MDL-009-005018	AGEL-MDL-009-005023	6/13/2007	PowerPoint entitled Besins Discussion Topics	
DX282	SLV357431	SLV357431	6/11/2007	Email from Murray Kay to Laurie Downey	
DX283	SLV357432	SLV357437	6/13/2007	PowerPoint entitled Besins Discussion Topics	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX284	SLV583611	SLV583686	6/19/2007	PowerPoint entitled Cardio-Metabolic and Specialized Markets Business Unit GPSD Meeting	Amyot 08 (4/29/2015)
DX285	PAR-MDL-00008643	PAR-MDL-00008645	6/20/2007	Email from Leslie Koby to Nefertiti Greene (with attachment)	MacPhee 36 (3/18/2016); Greene 18 (9/2/2015); Tupman 9 (9/15/2016); Reed 11 (11/16/2016)
DX286	SLV582196	SLV582197	6/25/2007	Email from Jay Bua to Laurie Downey and Thomas MacAllister	Bua 16 (4/20/2016)
DX287	SLV508633	SLV508636	6/28/2007	Email from Lynn Dale to Bill Mink	
DX288	SLV333530	SLV333566	7/11/2007	PowerPoint entitled 2007 BF2 2008-2012 Version 1	Hynd 34 (4/7/2016)
DX289	WTN0334794	WTN0334836	7/18/2007	Promotion Agreement between Depomed, Inc. and Watson Pharma, Inc.	
DX290	AGEL-MDL-024-001376	AGEL-MDL-024-001376	8/6/2007	Email from Vincent Amyot to Mark Hastings, et al.	
DX291	AGEL-MDL-024-001377	AGEL-MDL-024-001377	8/6/2007	JCC Meeting Minutes (Solvay/Watson) for August 22, 2007 meeting	
DX292	PAR-MDL-00013987	PAR-MDL-00013989	8/9/2007	Email from Nefertiti Greene to Carmen Bowen	Greene 04 (9/2/2015)
DX293	WTN0357660	WTN0357660	8/14/2007	Solvay-Watson JCC Meeting	
DX294	AGEL-MDL-024-001388	AGEL-MDL-024-001389	8/21/2007	JCC Meeting Minutes (Watson/Solvay) for August 14, 2007 meeting	
DX295	WTN00291347	WTN00291373	8/24/2007	Service Agreement	Heimers 21 (3/21/2016); Tykot 40 (2/23/2016)
DX296	GALD-AGEL000007	GALD-AGEL000036	8/27/2007	Service Agreement between Watson and Galderma including Amendment 1	
DX297	AGEL-MDL-021-020952	AGEL-MDL-021-020986	8/30/2007	JCC Meeting Minutes (Solvay/Par) for August 24, 2007 meeting	
DX298	WTN0334837	WTN0334880	9/21/2007	Amended and Restated Promotion Agreement	Heimers 20 (3/21/2016)
DX299	AGEL-MDL-014-032909	AGEL-MDL-014-032909	9/24/2007	Email from Jim Hynd to Brian Mitchell	
DX300	AGEL-MDL-015-005531	AGEL-MDL-015-005532	9/24/2007	PowerPoint slides entitled Androgel Continues to Accelerate as a Result of Project Inspire Initiative [Alt Bates AGEL-MDL-014-032910]	
DX301	PAR-MDL-00029315	PAR-MDL-00029315	10/15/2007	Memorandum from Carmen Bowen to Vincent Amyot, et al. re Solvay Proposal Action Items	Greene 26 (9/2/2015)
DX302	AGEL-MDL-015-022259	AGEL-MDL-015-022261	11/15/2007	JCC Meeting Minutes (Strativa/Solvay) for November 15, 2007 meeting	
DX303	WTN0361976	WTN0361976	12/17/2007	Solvay/Watson JCC Meeting, Bringing Low-T into Focus, December 17, 2007	
DX304	WTN0451870	WTN0451872	12/17/2007	Watson & Solvay, Minutes of the Working Session	
DX305	WTN0287544	WTN0287559	12/31/2007	Attachment 5-10 [Govt. Exhibit 2010]	Gov Ex 2010
DX306	WTN0287560	WTN0287576	12/31/2007	Attachment 5-12 [Govt. Exhibit 2011]	Gov Ex 2011
DX307	WTN0583008	WTN0583008	12/31/2007	Product Line Financial Statements YTD as of December 31, 2007	Yeomans 21 (5/4/2016)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX308	AGEL-MDL-021-009545	AGEL-MDL-021-009547	1/2/2008	JCC Meeting Minutes (Watson/Solvay) for December 17, 2007 meeting	
DX309	AGEL-MDL-008-006341	AGEL-MDL-008-006343	2/19/2008	JCC Meeting Minutes (Abbott/Strativa) for January 29, 2008 meeting	
DX310	AGEL-MDL-015-011816	AGEL-MDL-015-011817	3/14/2008	Email from Carmen Bowen to Stephen Krull, et al.	
DX311	AGEL-MDL-015-011818	AGEL-MDL-015-011820	3/14/2008	JCC Meeting Minutes (Abbott/Strativa) for January 29, 2008 meeting [draft]	
DX312	WTN0361806	WTN0361806	4/1/2008	Solvay Pharmaceuticals, Sales Strategy, Watson JCC Meeting, AndroGel Urology Market and Watson Call Plan Performance Diagnostics	
DX313	ABBVIE-AGEL02911541	ABBVIE-AGEL02911566	4/9/2008	PowerPoint entitled Executive Committee Meeting and Business Review	Hynd 29 (4/7/2016)
DX314	WTN0361813	WTN0361814	4/16/2008	Solvay/Watson JCC Meeting	
DX315	WTN0361879	WTN0361881	4/16/2008	Solvay/Watson JCC Meeting Minutes	
DX316	WTN0361942	WTN0361942	4/16/2008	AndroGel JCC Meeting Sales Operations Update presentation.	
DX317	WTN0398558	WTN0398558	4/16/2008	AndroGel JCC Meeting, Sales Operation Update, April 16, 2008	
DX318	AGEL-MDL-015-018943	AGEL-MDL-015-018943	4/16/2008	JCC Meeting Minutes (Solvay & Watson) for April 16, 2008 meeting	
DX319	AGEL-MDL-013-034582	AGEL-MDL-013-034582	4/22/2008	Email from Brian Mitchell to Kumar Kantheti and Jorge Gomez	
DX320	AGEL-MDL-013-034583	AGEL-MDL-013-034663	4/21/2008	Document entitled AndroGel Marketing Strategy	Cremieux 07 (4/6/2017)
DX321	AGEL-MDL-015-012103	AGEL-MDL-015-012106	5/12/2008	Email from Stephen Krull to Kevin Guthrie, et al. (with attachment)	Krull 03 (11/18/2015)
DX322	WTN0594231	WTN0594243	5/14/2008	Testosterone Gel 1% (Project #1529) Cross Functional Pre-Submission Team Meeting Minutes	
DX323	WTN0594217	WTN0594229	5/28/2008	Testosterone Gel 1% (Project #1529) Cross Functional Pre-Submission Team Meeting Minutes	Petrie 10 (3/16/2016)
DX324	WTN0361935	WTN0361935	6/1/2008	Solvay-Watson AndroGel JCC, Co-Promotion Analytics, June 18, 2008	
DX325	AGEL-MDL-008-006462	AGEL-MDL-008-006462	6/16/2008	JCC Meeting Minutes (Solvay/Watson) for June 18, 2008 meeting	
DX326	WTN0392121	WTN0392122	6/18/2008	Solvay/Watson JCC Meeting	
DX327	WTN0397949	WTN0397949	6/18/2008	AndroGel JCC Meeting, Sales Operations Update, June 18, 2008	
DX328	WTN0397956	WTN0397957	6/18/2008	Solvay/Watson JCC Meeting	
DX329	AGEL-MDL-015-022192	AGEL-MDL-015-022194	7/9/2008	JCC Meeting Minutes (Strativa/Solvay) for June 12, 2008 meeting	
DX330	AGEL-MDL-015-012423	AGEL-MDL-015-012427	7/11/2008	JCC Meeting Minutes (Solvay & Watson) for June 18, 2008 meeting [draft]	
DX331	AGEL-MDL-015-019246	AGEL-MDL-015-019246	9/8/2008	Email from Stephen Krull to Brian Mitchell	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX332	AGEL-MDL-015-019270	AGEL-MDL-015-019270	9/8/2008	JCC Meeting Minutes (Solvay & Watson) for September 10, 2008 meeting	
DX333	PFE00598	PFE00599	9/4/2008	Letter from Pfizer to Paddock Labs	Picurro 15 (12/4/2015)
DX334	WTN0392444	WTN0392444	9/10/2008	AndroGel JCC Meeting, Sales Operations Update, September 10, 2008	
DX335	WTN0397081	WTN0397082	9/10/2008	Solvay/Watson JCC Meeting	
DX336	WTN0525022	WTN0525024	9/10/2008	Solvay and Watson, Draft JCC Meeting Minutes	
DX337	PAR-MDL-00048177	PAR-MDL-00048177	9/29/2008	JCC Meeting Minutes (Solvay/Strativa) for October 2, 2008 meeting	
DX338	AGEL-MDL-014-033526	AGEL-MDL-014-033576	10/8/2008	PowerPoint entitled Executive Committee Meeting and Business Review	
DX339	AGEL-MDL-008-006499	AGEL-MDL-008-006502	10/17/2008	Email from Stephen Krull to Jean-Louis Anspach (with attachment)	Krull 06 (11/18/2015)
DX340	PAR-MDL-00184213	PAR-MDL-00184213	12/2/2008	Email from Erin Capra to John Macphee, et al.	MacPhee 16 (3/18/2016); MacPhee 30 (3/18/2016)
DX341	PAR-MDL-00184214	PAR-MDL-00184214	12/2/2008	Spreadsheet entitled 2009 Strativa P&L by Product.xls	
DX342	WTN0357756	WTN0357757	12/10/2008	Solvay/Watson JCC Meeting	
DX343	WTN0361896	WTN0361897	12/10/2008	Solvay/Watson JCC Meeting	
DX344	ABBVIE-AGEL00515532	ABBVIE-AGEL00515534	12/11/2008	JCC Meeting Minutes (Strativa/Solvay) for December 11, 2008 meeting [draft]	
DX345	AGEL-MDL-015-022322	AGEL-MDL-015-022322	1/13/2009	Email from Stephen Krull to Jean-Louis Anspach	
DX346	AGEL-MDL-015-022323	AGEL-MDL-015-022327	1/13/2009	JCC Meeting Minutes (Solvay/Watson) for December 10, 2008 meeting	
DX347	WTN0295569	WTN0295646	1/20/2009	Email from J. Williamson to A. Boyer attaching Watson Pharmaceuticals, Inc. Executive Financial Reporting Package Fourth Quarter - 2008	Yeomans 20 (5/4/2016)
DX348	ABBVIE-AGEL00671517	ABBVIE-AGEL00671519	1/29/2009	Letter from FDA to Unimed Pharmaceuticals re NDA 21-015	Dale 08 (5/11/2016)
DX349	WTN0392150	WTN0392150	3/3/2009	Solvay-Watson AndroGel JCC Meeting, Co-Promotion Analytics	
DX350	WTN0450131	WTN0450133	3/3/2009	Solvay and Watson DRAFT JCC Meeting Minutes	
DX351	WTN0537608	WTN0537608	3/3/2009	Solvay-Watson JCC Meeting, AndroGel Co-Promotion, Derek Rieder, Associate Product Manager, AndroGel, March 3, 2009	
DX352	ABBVIE-AGEL00144754	ABBVIE-AGEL00144754	3/3/2009	JCC Meeting Minutes (Solvay/Watson) for March 3, 2009 meeting	
DX353	PADD-MDL-00012000	PADD-MDL-00012001	3/19/2009	Letter from FDA to Unimed Pharmaceuticals re NDA 21-015	
DX354	PADD-MDL-00008494	PADD-MDL-00008495	3/25/2009	Email from Patrick Kaczaral to Hanspeter Dietschi (with attachment)	Dale 11 (5/11/2016)
DX355	WTN0357173	WTN0357173	3/29/2009	Email from L. Amato to E. Heiemrs	Amato 17 (8/26/2015)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX356	ABBVIE-AGEL02801390	ABBVIE-AGEL02801429	4/8/2009	PowerPoint entitled Executive Committee Meeting and Business Review	Hynd 32 (4/7/2016)
DX357	PADD-MDL-00008621	PADD-MDL-00008622	4/15/2009	Email from Patrick Kaczal to Bill Mink, et al.	Dale 09 (5/11/2016)
DX358	PAR-MDL-00185627	PAR-MDL-00185627	4/20/2009	Spreadsheet entitled 2009 Strativa P&L by Product.xls	
DX359	ABBVIE-AGEL01803338	ABBVIE-AGEL01803342	5/18/2009	JCC Meeting Minutes (Abbott/Strativa) for April 20, 2009 meeting [draft]	
DX360	WTN0361908	WTN0361908	6/1/2009	Solvay-Watson AndroGel JCC Meeting, Co-Promotion Analytics, June 2009	
DX361	WTN0537623	WTN0537624	6/23/2009	Watson/Solvay JCC Meeting Minutes	
DX362	WTN0451946	WTN0451947	6/23/2009	Watson/Solvay JCC Meeting Minutes	
DX363	WTN0361934	WTN0361934	9/1/2009	Solvay-Watson AndroGel JCC Meeting, Co-Promotion Analytics, September 2009	
DX364	WTN0357754	WTN0357755	9/17/2009	Solvay/Watson DRAFT JCC Meeting Minutes	
DX365	SLV054198	SLV054201	6/8/2006	Par Overlap Analysis Presentation	
DX366	PAR-MDL-00162635	PAR-MDL-00162637	9/30/2009	Email from Paul Campanelli to Matthew Zrebiec, et al.	Jaskot 30 (10/18/2016)
DX367	PAR-MDL-00185626	PAR-MDL-00185627	4/20/2009	Email from Erin Capra to Nefertiti Greene	Greene 31 (9/2/2015); MacPhee 17 (3/18/2016); Tupman (9/15/2016); Reed 05 (11/16/2016)
DX368	PAR-MDL-00187841	PAR-MDL-00187842	10/20/2009	Email from Christina Moretto to John MacPhee, et al.	MacPhee 19 (3/18/2016); Greene 32 (9/2/2015); Reed 06 (11/16/2016)
DX369	PAR-MDL-00187843	PAR-MDL-00187843	10/20/2009	Spreadsheet entitled 2010 Operating Plan- P&L by Product.xls	
DX370	WTN0392062	WTN0392062	12/1/2009	Solvay-Watson AndroGel JCC Meeting, Co-Promotion Analytics, December 2009	
DX371	WTN0361820	WTN0361821	12/5/2009	Solvay/Watson JCC Meeting Teleconference	
DX372	WTN0393507	WTN0393507	12/15/2009	2010 Sales Force Alignmnet & Androgel PR Opportunity	
DX373	WTN0537616	WTN0537616	12/15/2009	Watson JCC Meeting, December 15, 2009, Derek Rieder, Associate Product Manager, AndroGel	
DX374	WTN0583105	WTN0583105	12/31/2009	Brand Product Line Financial Statements YTD as of December 31, 2009	Yeomans 22 (5/4/2016)
DX375	PAR-MDL-00000324	PAR-MDL-00000325	1/5/2010	Letter from Par to CDER re ANDA 076744	
DX376	WTN0357656	WTN0357657	2/19/2010	2.19.10 Watson/Abbott JCC Meeting Action Items	
DX377	WTN0361955	WTN0361955	3/1/2010	Watson 2010 Call Plan Analysis, March 2010	
DX378	WTN0357730	WTN0357730	3/9/2010	Solvay/Watson JCC Meeting	
DX379	WTN0393542	WTN0393542	3/9/2010	Solvay/Watson JCC Meeting	
DX380	WTN0592407	WTN0592407	3/24/2010	Alternate API Summary Report	Petrie 33 (3/16/2016)
DX381	ABBVIE-AGEL00956290	ABBVIE-AGEL00956290	3/25/2010	JCC Meeting Minutes (Abbott/Watson) for March 9, 2010 meeting	
DX382	WTN0363728	WTN0363731	5/21/2010	Email from S. Renna to L. Amato and C. Yeomans re: 2007-2010 AndroGel Call Plan Productivity Analysis	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX383	WTN0363732	WTN0363732	5/21/2010	2007 - 2010 AndroGel Call Plan Productivity Analysis	
DX384	WTN0363702	WTN0363702	6/1/2010	Sales Ops, Watson S1 2010 JCC, June 2010	
DX385	PAR-MDL-00174396	PAR-MDL-00174396	6/23/2010	Email from Julie Szozda to Michelle Bonomi, et al.	Jaskot 22 (10/18/2016)
DX386	WTN0395234	WTN0395251	6/28/2010	Abbott/Watson Joint Commercial Committee, AndroGel Update, June 28, 2010	
DX387	ABBVIE-AGEL02782276	ABBVIE-AGEL02782276	7/2/2010	Email from Frank Jaeger to Jim Hynd	
DX388	ABBVIE-AGEL02782277	ABBVIE-AGEL02782286	7/2/2010	Document entitled AndroGel (testosterone gel) 1% CIII 2011 Business Plan - Draft Executive Summary	
DX389	ABBVIE-AGEL01674788	ABBVIE-AGEL01674788	7/16/2010	JCC Meeting Minutes (Abbott/Strativa) for July 23, 2010 meeting [draft]	
DX390	WTN0363310	WTN0363310	9/1/2010	Watson 2010 Q3 JCC, September 2010	
DX391	WTN0363701	WTN0363701	9/1/2010	Abbott/Watson JCC Meeting, September 2010	
DX392	PAR-MDL-00176040	PAR-MDL-00176040	9/10/2010	Email from Julie Szozda to Inna Gruber, et al.	Jaskot 23 (10/18/2016)
DX393	WTN0440894	WTN0440896	10/15/2010	Generic Ops Meeting Minutes	Petrie 35 (3/16/2016)
DX394	PADD-MDL-00011992	PADD-MDL-00012001	11/16/2010	Email from from Lincy Michael to Patrick Kaczaral, et al. (with attachment)	Dale 10 (5/11/2016); Mink 39 (10/2/2015)
DX395	PAR-MDL-00189782	PAR-MDL-00189783	11/19/2010	Email from Marian Gustafson to Erin Zaccaro, et al.	MacPhee 33 (3/18/2016)
DX396	PAR-MDL-00092120	PAR-MDL-00092137	12/7/2010	PowerPoint entitled Strativa Pharmaceuticals 2010 Highlights	
DX397	WTN0363102	WTN0363103	12/14/2010	Abbott/Watson JCC Meeting	
DX398	WTN0392967	WTN0392967	12/14/2010	Fourth Quarter AndroGel JCC Meeting, December 14, 2010	
DX399	WTN0583138	WTN0583138	12/31/2010	Global Brand Product Line Financial Statement YTD as of December 31, 2010	Yeomans 23 (5/4/2016)
DX400	PAR-MDL-00177384	PAR-MDL-00177384	1/4/2011	Email from Allison Wey to Paul Campanelli	
DX401	PAR-MDL-00177385	PAR-MDL-00177385	1/4/2011	PowerPoint entitled Par Pharmaceutical Companies (at JP Morgan 2011 Healthcare Conference)	
DX402	ABBVIE-AGEL01111333	ABBVIE-AGEL01111369	1/20/2011	PowerPoint entitled Metabolic/GI Care Business Review 2010 Actual & 2011 Plan	
DX403	PAR-MDL-00177612	PAR-MDL-00177612	1/13/2011	Email from Julie Szozda to Inna Gruber, et al.	Picurro 17 (12/4/2015)
DX404	WTN0332444	WTN0332449	1/31/2011	Prior approval supplement	Petrie 8 (3/16/2016)
DX405	PAR-MDL-00178299	PAR-MDL-00178299	2/22/2011	Email from Allison Wey to Paul Campanelli	
DX406	PAR-MDL-00178300	PAR-MDL-00178300	3/1/2011	PowerPoint entitled Par Pharmaceutical Companies (at Citi Global Healthcare Conference)	
DX407	WTN0393258	WTN0393258	3/8/2011	2011 Q1 AndroGel JCC Meeting, March 8, 2011	
DX408	WTN0395084	WTN0395084	3/8/2011	Abbott/Watson JCC Meeting	
DX409	PAR-MDL-00000596	PAR-MDL-00000598	6/7/2011	Letter from FDA to Par Pharmaceutical, Inc. re ANDA 076744/S-002	Picurro 18 (12/4/2015)
DX410	AGEL-MDL-027-000001	AGEL-MDL-027-000004	7/6/2011	PowerPoint slides entitled 2009 Demonstrated What is Possible with Unbranded DTC	
DX411	AGEL-MDL-027-000274	AGEL-MDL-027-000346	7/6/2011	PowerPoint slides entitled AndroGel DTC Campaign Results: Final Analysis Presentation 4/23/09 - 7/31/09	
DX412	WTN0392971	WTN0392971	7/19/2011	2011 Q3 AndroGel JCC Meeting, July 19, 2011	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX413	WTN0449304	WTN0449304	7/19/2011	Abbott/Watson JCC Meeting, Game Changer, July 19, 2011	
DX414	ABBVIE-AGEL03143647	ABBVIE-AGEL03143675	7/20/2011	Email from Frank Jaeger to Margaret Dambrosia, et al. (with attachment)	Jaeger 41 (5/6/2016)
DX415	ABBVIE-AGEL00352476	ABBVIE-AGEL00352555	7/22/2011	PowerPoint entitled AndroGel Patient Cost Sensitivity and Managed Markets Strategy Support Phase 1: Executive Summary	
DX416	PAR-MDL-00193219	PAR-MDL-00193244	7/27/2011	Amended and Restated Manufacturing and Supply Agreement between Par Pharmaceuticals, Inc. and Paddock Laboratories LLC	
DX417	WTN0393082	WTN0393082	8/12/2011	AndroGel Message Recall Research (Results thru August 12, 2011), Marketing Analytical & Business Insights	
DX418	ABBVIE-AGEL00060667	ABBVIE-AGEL00060694	9/14/2011	PowerPoint entitled 2012 AndroGel 1.62% Brand Plan (28-page version) [Alt Bates ABBVIE-AGEL00060610-60637]	
DX419	ABBVIE-AGEL00010133	ABBVIE-AGEL00010170	9/14/2011	PowerPoint entitled 2012 AndroGel 1.62% Brand Plan (38-page version)	Gautsch 09 (5/18/2016)
DX420	ABBVIE-AGEL00990557	ABBVIE-AGEL00990881		PowerPoint entitled 2012 AndroGel 1.62% Brand Plan (325-page version)	
DX421	WTN0394730	WTN0394730	9/19/2011	Abbott/Watson JCC Meeting	
DX422	ABBVIE-AGEL00951877	ABBVIE-AGEL00951879	9/19/2011	JCC Meeting Minutes (Abbott/Watson) for September 19, 2011 meeting [draft]	
DX423	WTN0583157-001	WTN0583157-003	9/30/2011	Global Brand Product Line Financial Statement YTD as of September 30, 2011	Yeomans 11 (5/4/2016)
DX424	WTN0392163	WTN0392163	12/12/2011	AndroGel 1.62% Update, JCC Meeting - December 12, 2011	
DX425	WTN0394668	WTN0394669	12/14/2011	Abbott/Watson JCC Meeting	
DX426	ABBVIE-AGEL02045675	ABBVIE-AGEL02045844	1/11/2012	PowerPoint entitled 2011 Strategic Business Plan (AndroGel Marketing Team)	
DX427	ABBVIE-AGEL00048115	ABBVIE-AGEL00048115	2/2/2012	Screen shot of "IsItLowT.com - Could you have Low T?"	
DX428	ABBVIE-AGEL00344472	ABBVIE-AGEL00344477	2/2/2012	Screen shot of "IsItLowT.com -Treatment Options"	
DX429	CVS-ANDRO-0067491	CVS-ANDRO-0067496	4/1/2012	Spreadsheet entitled Fortesta Sales Increase Analysis	Griffin 16 (3/16/2016)
DX430	WTN0394582	WTN0394582	4/8/2012	Abbott Watson JCC Meeting Q1 '12. April 8, 2012	
DX431	WTN0358612	WTN0358613	4/9/2012	Abbott/Watson JCC Meeting Minutes	
DX432	WTN0394590	WTN0394591	4/9/2012	Abbott/Watson JCC Meeting	
DX433	ABBVIE-AGEL00502719	ABBVIE-AGEL00502720	4/9/2012	JCC Meeting Minutes (Abbott/Watson) for April 9, 2012 meeting	
DX434	ABBVIE-AGEL00722383	ABBVIE-AGEL00722383	4/9/2012	JCC Meeting Minutes (Abbott/Watson) for April 9, 2012 meeting	
DX435	ABBVIE-AGEL00995220	ABBVIE-AGEL00995544	4/18/2012	PowerPoint entitled 2012 AndroGel 1.62% Business Plan	
DX436	BESINS-FTC-SUB2015-0000005	BESINS-FTC-SUB2015-0000006	5/4/2012	Email from Leslie Grunfeld to Charles Gancel	Bua 11 (4/20/2016)
DX437	WTN0379435	WTN0379435	5/30/2012	Email from M. Allard to S. Krull, V. Sanford, E. Pluckhorn, and S. Scibilia re: 4 9 12 JCC minutes Watson additions attaching DRAFT Minutes 4 9 12 JCC Meeting MA notes.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX438	WTN0379436	WTN0379437	5/30/2012	DRAFT Minutes 4 9 12 JCC Meeting MA notes.	
DX439	CVS-ANDRO-0067489	CVS-ANDRO-0067490	5/30/2012	Email from Cathy Pettis to Stephen Heidenthal	Griffin 15 (3/16/2016)
DX440	ABBVIE-AGEL03265016	ABBVIE-AGEL03265165	6/15/2012	PowerPoint entitled AndroGel GPO Strategic Plan	Gautsch 07 (5/18/2016)
DX441	WTN0353163	WTN0353163	7/12/2012	Email from L Marion to V. Sanford re: Androderm 2013 Planning meeting attaching Androderm 2 mg/4 mg 2013 Planning Meeting presentation.	
DX442	WTN0353164	WTN0353164	7/12/2012	Androderm 2 mg/4 mg 2013 Planning Meeting presentation.	
DX443	ABBVIE-AGEL00951873	ABBVIE-AGEL00951874	8/18/2012	JCC Meeting Minutes (Abbott/Watson) for April 9, 2012 meeting [Watson's edits to draft minutes]	
DX444	ABBVIE-AGEL00951880	ABBVIE-AGEL00951880	8/18/2012	JCC Meeting Minutes (Abbott/Watson) for August 20, 2012 meeting [draft]	
DX445	WTN0392935	WTN0392935	8/20/2012	Abbott/Watson, JCC Meeting, August 20, 2012	
DX446	ABBVIE-AGEL00026297	ABBVIE-AGEL00026347	9/5/2012	Email from Meena Valravan to James B. Hynd, et al. (with attachment)	Hynd 16 (4/6/2016)
DX447	WTN0359366	WTN0359366	11/29/2012	Abbott/Watson JCC Meeting	
DX448	WTN0392161	WTN0392161	11/29/2012	AndroGel 1.62% Update, JCC Meeting - November 29, 2012	
DX449	WTN0449972	WTN0449976	11/29/2012	Abbott/Watson JCC Meeting	
DX450	ABBVIE-AGEL00712715	ABBVIE-AGEL00712731	12/31/2012	Amended and Restated Sublicense Agreement between Abbott Laboratories and Unimed Pharmaceuticals, LLC	
DX451	ABBVIE-AGEL00712732	ABBVIE-AGEL00712742	12/31/2012	Special Products Specific Agreement between Abbott Laboratories and AbbVie, Inc.	
DX452	ABBVIE-AGEL01161225	ABBVIE-AGEL01161328	12/31/2012	Finished Goods Supply Agreement for AndroGel between Unimed Pharmaceuticals, LLC and Abbott Products Operations AG	
DX453	BESINS-FTC-SUB2015-0003853	BESINS-FTC-SUB2015-0003861	2013-2014	Delpharm invoices to Besins	Bua 09 (4/20/2016)
DX454	ABBVIE-AGEL01790407	ABBVIE-AGEL01790447	1/11/2013	PowerPoint entitled TRT Patient Metrics	
DX455	BESINS-FTC-SUB2015-0003865	BESINS-FTC-SUB2015-0003865		Spreadsheet entitled Investments: Back Up DELPHARM LILLE by vouchers	Bua 08 (4/20/2016)
DX456	BESINS-FTC-SUB2015-0000508	BESINS-FTC-SUB2015-0000511	1/9/2013	Email from Carl Tatsuguchi to Daniel Delarbre	Bua 04 (4/20/2016)
DX457	ABBVIE-AGEL00521343	ABBVIE-AGEL00521356	2/7/2013	PowerPoint entitled AndroGel Delpharm Site Transfer	
DX458	WTN0357325	WTN0357328	3/4/2013	AbbVie/Actavis JCC Meeting	
DX459	WTN0359607	WTN0359607	3/4/2013	Abbott/Actavis JCC Meeting Agenda	
DX460	WTN0359687	WTN0359688	3/4/2013	Email from V. Giafanella re: JCC deck v4 attaching JCC Watson March 2013 MASTER v5 FINAL presentation.	
DX461	WTN0359689	WTN0359689	3/4/2013	JCC Watson March 2013 MASTER v5 FINAL presentation	
DX462	WTN0359699	WTN0359699	3/4/2013	AndroGel 1.62% Marketing Update, March 4, 2013	
DX463	ABBVIE-AGEL00089975	ABBVIE-AGEL00089978	3/4/2013	JCC Meeting Minutes (AbbVie/Actavis) for March 4, 2013 meeting [draft]	
DX464	ABBVIE-AGEL00981074	ABBVIE-AGEL00981076	3/7/2013	Email from Samantha Chan to Michael Douma, et al.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX465	ABBVIE-AGEL00045101	ABBVIE-AGEL00045107	3/20/2013	PowerPoint entitled AndroGel Operations Extended Brand Team Meeting	
DX466	WTN0567895-001	WTN0567895-006	3/31/2013	Global Brand Product Line Financial Statement for the First Quarter Ended March 31, 2013	Yeomans 14 (5/4/2016)
DX467	ABBVIE-AGEL00889287	ABBVIE-AGEL00889287	5/27/2013	Email from Jim Hynd to Marty Comer, et al.	
DX468	ABBVIE-AGEL00889290	ABBVIE-AGEL00889323	5/27/2013	PowerPoint entitled AndroGel 2013 Early Performance Summary, attachment to ABBVIE-AGEL00889287	
DX469	ABBVIE-AGEL00591181	ABBVIE-AGEL00591185	06/00/2013	PowerPoint entitled Besins Project at Delpharm Lille	
DX470	WTN0360602	WTN0360604-006	7/9/2013	Email from C. Yeomans attaching Global Brand Product Line Financial Statement for the First Quarter Ended March 31, 2012	Yeomans 12 (5/4/2016)
DX471	ABBVIE-AGEL01475683	ABBVIE-AGEL01475745	7/11/2013	PowerPoint entitled Growing Competitive Set	
DX472	WTN0357348	WTN0357350	7/26/2013	Abbott/Actavis JCC Meeting	
DX473	WTN0360796	WTN0360796	7/26/2013	Abbott/Actavis JCC Meeting	
DX474	WTN0360829	WTN0360830	7/26/2013	Email from V. Gialanella re: Deck for JCC Meeting attaching JCC Presentations Final presentation.	
DX475	WTN0360831	WTN0360831	7/26/2013	JCC Presentations Final presentation.	
DX476	ABBVIE-AGEL00349883	ABBVIE-AGEL00349932	09/00/2013	AndroGel Injectable Behavior Study	
DX477	WTN0392271	WTN0392271	7/26/2013	AndroGel JCC Meeting, July 26th 2013	
DX478	WTN0411301	WTN0411303	9/9/2013	Letter from FDA to Watson Laboratories, Inc.	
DX479	ABBVIE-AGEL01647047	ABBVIE-AGEL01647047	10/16/2013	Spreadsheet entitled M09 monthly financial statement.xls	
DX480	ABBVIE-AGEL00520383	ABBVIE-AGEL00520395	10/29/2013	PowerPoint entitled AndroGel Delpharm Phase I	
DX481	ABBVIE-AGEL00520396	ABBVIE-AGEL00520398	10/29/2013	PowerPoint entitled AndroGel Delpharm Phase II	
DX482	ABBVIE-AGEL00521406	ABBVIE-AGEL00521410	11/4/2013	Document entitled Regulatory Strategy CMC Small Molecule Post Approval Change	
DX483	ABBVIE-AGEL00262728	ABBVIE-AGEL00262728	2/26/2014	Email from Lisa Wortschmann to Michael Gautsch (cc: Louis Lipinski) (without attachment)	Lipinski 04 (5/19/2016)
DX484	ABBVIE-AGEL00345295	ABBVIE-AGEL00345295	2/26/2014	Spreadsheet entitled AndroGel Historical Information 2004-2010	Lipinski 05 (5/19/2016)
DX485	ABBVIE-AGEL00783675	ABBVIE-AGEL00783678	2/28/2014	Letter from FDA to AbbVie Inc. re NDA 22309/S-010	
DX486	WTN0334591	WTN0334596	4/4/2014	Minor Complete Response Amendment	
DX487	WTN0353126	WTN0353126	4/8/2014	AbbVie + Actavis JCC Meeting, April 8, 2014	
DX488	WTN0353127	WTN0353127	4/8/2014	Abbott/Actavis JCC Meeting	
DX489	WTN0353796	WTN0353796	4/8/2014	AbbVie & Actavis Quarterly JCC Meeting Agenda	
DX490	ABBVIE-AGEL00897192	ABBVIE-AGEL00897192	4/8/2014	JCC Meeting Minutes (Abbott/Actavis) for April 8, 2014 meeting	
DX491	ABBVIE-AGEL03260979	ABBVIE-AGEL03260981	5/27/2014	JCC Meeting Minutes (Abbott/Actavis) for July 26, 2013 meeting	
DX492	ABBVIE-AGEL02622813	ABBVIE-AGEL02622823	6/26/2014	Document entitled "Providing Clarify and Direction" 2015 AndroGel 1.62% Strategic Narrative	Gautsch 21 (5/18/2016)
DX493	WTN0390275	WTN0390275	7/16/2014	AbbVie & Actavis Quarterly JCC Meeting	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX494	WTN0524481	WTN0524520	7/16/2014	AbbVie Actavis JCC Meeting, Indigo Hotel, Vernon Hills, IL, July 16, 2014	
DX495	ABBVIE-AGEL00860677	ABBVIE-AGEL00860678	7/15/2014	Email from Michael Gautsch to Pablo Hernandez	
DX496	ABBVIE-AGEL02375303	ABBVIE-AGEL02375326	7/16/2014	PowerPoint entitled AbbVie Actavis JCC Meeting [Alt Bates ABBVIE-AGEL00860679]	
DX497	ABBVIE-AGEL00475787	ABBVIE-AGEL00475788	7/18/2014	Email from James Hanson to Katherine Manchester, et al.	
DX498	ABBVIE-AGEL00475789	ABBVIE-AGEL00475803	7/16/2014	PowerPoint entitled AbbVie + Actavis JCC Meeting (July 16, 2014)	
DX499	WTN0367686	WTN0367688	8/7/2014	Approval letter re: prior approval supplement	Petrie 9 (3/16/2016)
DX500	ABBVIE-AGEL00049702	ABBVIE-AGEL00049702	8/14/2014	Spreadsheet entitled TRT Historical Data January 2000 to July 2014 - to Steve Niemcryk.xlsx	
DX501	PAR-MDL-00213777	PAR-MDL-00213779	9/18/2014	Letter from Par to CDER re ANDA 076744	
DX502	ABBVIE-AGEL00716276	ABBVIE-AGEL00716277	8/25/2014	Email from Lisa Marzano to Janet Hollinger, et al.	
DX503	ABBVIE-AGEL00716278	ABBVIE-AGEL00716328	8/25/2014	PowerPoint entitled TRT Patient Metrics	
DX504	ABBVIE-AGEL00959662	ABBVIE-AGEL00959674	2/26/2015	PowerPoint entitled AndroGel - Besins & Supply Chain	
DX505	PAR-MDL-00214099	PAR-MDL-00214100	4/2/2015	Letter from Par to CDER re Amendment to a Prior Approval Supplement ANDA 076744	
DX506	AGEL-MDL-014-024149	AGEL-MDL-014-024154	8/31/2015	PowerPoint entitled Project Tulip [Alt Bates SLV582313-SLV582318]	Govt Ex. 0297 [SLV582313-SLV582318]
DX507	ABBVIE-AGEL03267224	ABBVIE-AGEL03267224		Spreadsheet AndroGel Historical Information 2004-2015	Lipinski 02 (5/19/2016)
DX508	PAR-MDL-00214122	PAR-MDL-00214123	4/13/2015	Letter from FDA to Par Pharmaceutical, Inc. re sANDA 076744/S-002 approval	Picurro 19 (12/4/2015)
DX509	SLV162278	SLV162286		PowerPoint entitled Solvay Pharmaceuticals, Inc. Product Strategy 2005-2009 Plan	Hynd 15 (8/18/2011)
DX510	WTN0007070	WTN0007123		New Products Business Plan 2006 presentation.	
DX511	WTN0106874	WTN0106913		Brand Portfolio 2007v.1 spreadsheet.	
DX512	WTN0360809	WTN0360809		Watson + Actavis, A Powerful Global Combination	
DX513	WTN0451128	WTN0451128		Performance Metrics Update, Solvay Pharmaceuticals	
DX514	WTN0570697	WTN0570697		AndroGel, Bringing Low-T Into Focus, John Rodda	
DX515	SLV587026	SLV587026		Spreadsheet entitled Urology Based Androgel Business [Alt Bates SLV587026-SLV587033, Govt Ex. 0290]	Govt Ex. 0290 A
DX516	SLV123484	SLV123512		Document entitled Watson Net Sales History & Estimates	Janco 35 (10/22/2015)
DX517	SLV581646	SLV581651		PowerPoint entitled Watson and Solvay: A Strategic Fit in Urology [Alt Bates SLV475126-SLV475131]	Govt Ex. 0286 (5/16/2008 Yang)
DX518	SLV301780	SLV301780		Email from Frederick Walthe to Jean-Louis Anspach, Jay Janco, et al.	
DX519	SLV301781	SLV301792		Document entitled Androgel Financial Planning Assumptions (Testim Generic - 10%)	Govt Ex. 0060
DX520	WTN0093301	WTN0093312		PowerPoint entitled Watson Field Force Strategy - A continued Specialty Focus	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX521			1/7/2003	U.S. Patent No. 6,503,894	Erstad 17 (2/8/2008); Kottayil 02; Hynd 03 (8/18/2011); Zeleny 16 (2/9/2005); Ebert 13 (3/2/2005); Goldstein 04 (11/4/2016); Gann 04; Mahoney 11; Mann 02 (2/8/2017); Mann 06 (1/12/2012); Powell 01 (2/24/2017)
DX522	UCFH 0001	UCFH 2820		U.S. Patent No. 6,503,894 prosecution history [Alt Bates PAR 045040-045793]	Mahoney 11 (5/10/2016)
DX523	ABBVIE-AGEL03247403	ABBVIE-AGEL03247506		U.S. Patent No. 9,125,816	
DX524	ABBVIE-AGEL03246024	ABBVIE-AGEL03247402		U.S. Patent No. 9,125,816 prosecution history	
DX525	ABBVIE-AGEL03249096	ABBVIE-AGEL03249198		U.S. Patent No. 9,132,089	
DX526	ABBVIE-AGEL03247507	ABBVIE-AGEL03249095		U.S. Patent No. 9,132,089 prosecution history	
DX527	ABBVIE-AGEL03114312	ABBVIE-AGEL03114315		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/942,245, April 10, 2015	McKelvie 36 (4/19/2017)
DX528	ABBVIE-AGEL03114416	ABBVIE-AGEL03114519		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/965,499, April 10, 2015	McKelvie 35 (4/19/2017)
DX529	ABBVIE-AGEL03114520	ABBVIE-AGEL03114525		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/942,245, May 14, 2015	McKelvie 40 (4/19/2017)
DX530	ABBVIE-AGEL03114526	ABBVIE-AGEL03114531		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/965,499, May 14, 2015	McKelvie 39 (4/19/2017)
DX531	ABBVIE-AGEL03114532	ABBVIE-AGEL03114542		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/942,245, August 16, 2013	McKelvie 38 (4/19/2017)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX532	ABBVIE-AGEL03114543	ABBVIE-AGEL03114553		Sealed Information Disclosure Statement by Applicant and Petition Request Under 37 C.F.R. 1.59(b) to Expunge Applications, Patent Application No. 13/965,499, August 16, 2013	McKelvie 37 (4/19/2017)
DX533	AGEL MDL 001-011879	AGEL MDL 001-011879		Excerpts from notebook containing Original Submission Corona ANDA - 76-737 [Alt Bates W 000140]	Ebert 12 (3/2/2005)
DX534	AGEL MDL 001-020214	AGEL MDL 001-020219		Watson laboratory notebook	Quan 14 (4/7/2005)
DX535	AGEL MDL 001-026622	AGEL MDL 001-026626		Skin Permeation 129-31 (Joel L. Zatz ed., 1993)	
DX536	AGEL MDL 001-026853	AGEL MDL 001-026861		Document entitled 6. Formulation Data [Alt Bates PAD 0003990-3992, PAD 0003993-3997, PAD 0003999]	Zeleny 05 (2/9/2005)
DX537	AGEL MDL 002-000309	AGEL MDL 002-000311		Paddock ANDA excerpt (comparison between RLD and proposed generic)	
DX538	AGEL MDL 002-000312	AGEL MDL 002-000313		Paddock ANDA excerpt (BE study report)	
DX539	AGEL MDL 002-000314	AGEL MDL 002-000338		Orange Book preface	
DX540	AGEL MDL 002-000346	AGEL MDL 002-000348	8/27/1999	UMD-96-017 study report	
DX541	AGEL MDL 002-000349	AGEL MDL 002-000352		Paddock ANDA excerpt (BE study report)	
DX542	AGEL MDL 002-000353	AGEL MDL 002-000383		Paddock ANDA excerpt (label comparison)	
DX543	AGEL MDL 002-000540	AGEL MDL 002-000540		AndroGel NDA excerpt	
DX544	AGEL MDL 002-000541	AGEL MDL 002-000543		Paddock ANDA excerpt (packaging)	
DX545	AGEL MDL 002-000720	AGEL MDL 002-000720		Watson ANDA excerpt (comparison between RLD and proposed generic)	
DX546	AGEL MDL 002-000882	AGEL MDL 002-000928		Watson ANDA excerpt (BE study report)	
DX547	AGEL MDL 002-000995	AGEL MDL 002-000997		Watson ANDA excerpt (packaging)	
DX548	AGEL MDL 002-002320	AGEL MDL 002-002328		Paddock ANDA excerpt (formulation data)	
DX549	AGEL MDL 002-002820	AGEL MDL 002-002824		Paddock ANDA excerpt (certificates of analysis)	
DX550	AGEL MDL 002-003116	AGEL MDL 002-003118		Watson ANDA excerpt (formulation data)	
DX551	AGEL MDL 002-003209	AGEL MDL 002-003236		Watson ANDA excerpt (certificates of analysis)	
DX552	AGEL MDL 002-003237	AGEL MDL 002-003241		Watson ANDA excerpt (label comparison)	
DX553	AGEL MDL 002-003242	AGEL MDL 002-003247		Watson ANDA excerpt (labeling)	
DX554	AGEL MDL 002-005935	AGEL MDL 002-005937		Noveon product literature	
DX555	AGEL MDL 002-005938	AGEL MDL 002-005940		Noveon product literature	
DX556	AGEL MDL 002-005941	AGEL MDL 002-005945		Noveon product literature	
DX557	AGEL MDL 002-005946	AGEL MDL 002-005956		Noveon product literature	
DX558	AGEL MDL 002-005961	AGEL MDL 002-005964		Noveon product literature	
DX559	AGEL MDL 002-005965	AGEL MDL 002-005967		Noveon product literature	
DX560	AGEL MDL 002-005968	AGEL MDL 002-005968		Noveon product literature	
DX561	AGEL MDL 002-006069	AGEL MDL 002-006077		Noveon product literature	
DX562	AGEL MDL 002-007900	AGEL MDL 002-007953		Medical Review for NDA No. 21-015	
DX563	AGEL MDL 002-007954	AGEL MDL 002-007959		Unimed FDA correspondence	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX564	AGEL MDL 002-000001	AGEL MDL 002-000034	4/25/2005	Expert Report of Loyd V. Allen, Jr.	
DX565	AGEL MDL 002-001153	AGEL MDL 002-001198	4/25/2005	Expert Report of Laurence M. Demers	
DX566	AGEL MDL 002-002109	AGEL MDL 002-002137	4/25/2005	Expert Report of Wylie C. Hembree	
DX567	AGEL MDL 002-003578	AGEL MDL 002-003623		Expert Report of Joel L. Zatz	
DX568	AGEL MDL 002-005322	AGEL MDL 002-005340	5/25/2015	Rebuttal Expert Report of Loyd V. Allen, Jr.	
DX569	AGEL MDL 002-008218	AGEL MDL 002-008260		Rebuttal Expert Report of Joel L. Zatz	
DX570				CV of Christopher Bowman, Ph.D.	
DX571				CV of Pierre Y. Cremieux, Ph.D.	
DX572				CV of Elizabeth C. Lindsey	
DX573				CV of Marianne C. Mann, M.D.	
DX574				CV of Roderick McKelvie	
DX575				CV of Michael Moffitt	
DX576				CV of Leslie Sandberg Orne	
DX577				CV of J. Robert Powell, Pharm.D.	
DX578				CV of Chad W.M. Ritenour, M.D.	
DX579				CV of Norman Weiner, Ph.D.	
DX580				CV of Kurt R. Karst	
DX581				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 1 January 13, 2017 report: Exhibit 1 - Summary of AndroGel Competitors.xlsx	
DX582				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 2 January 13, 2017 report: Exhibit 2 - AndroGel Patients with Other TRTs.xlsx	
DX583				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 3 January 13, 2017 report: Exhibit 3 - Switching to and from first and last AndroGel.xlsx	
DX584				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 4 January 13, 2017 report: Exhibit 4 - Patient Examples.xlsx	
DX585				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 5a-5b January 13, 2017 report: Exhibit 5 - TRT Total Trends by Type.xlsx	
DX586				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 6a-6b January 13, 2017 report: Exhibit 6 - AndroGel Share of TRTs.xlsx	
DX587				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 7 January 13, 2017 report: Exhibit 7 - Price Ratios.xlsx	
DX588				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 8a-8b January 13, 2017 report: Exhibit 8 - Promotional Spending of TRT Products.xlsx	
DX589				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 9a-9b January 13, 2017 report: Exhibit 9 - Promotional Spending as Percent of Sales of TRT Products.xlsx	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX590				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 10 January 13, 2017 report: Exhibit 10 - Project Tulip Exhibit.xlsx	
DX591				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 11 January 13, 2017 report: Exhibit 11 - Promotional Spending of TRT Products with Total Market Size.xlsx	
DX592				Data used by Pierre Y. Cremieux, Ph.D. to generate Exhibit 12a 12b January 13, 2017 report: Exhibit 12 – Consumer Welfare Model.xlsx	
DX593				INTENTIONALLY LEFT BLANK	
DX594				INTENTIONALLY LEFT BLANK	
DX595				Data used by Elizabeth C. Lindsey to generate chart on page 65 to January 13, 2017 report: Value Comparisons in Expert Report.xlsx	
DX596				Data used by Leslie Sandberg Orne to generate Figure 1 to January 13, 2017 report: 1. Copromotion Analysis 12.15.16.xlsx (backup for Appendix C)	
DX597				Data used by Leslie Sandberg Orne to generate Figure 2 to January 13, 2017 report: 5. Licensing Analysis 12.22.16.xlsx (backup for Appendix D)	
DX598				Data used by Leslie Sandberg Orne to generate Figure 3 to January 13, 2017 report: 2. Promotion Correlation Analysis 12.23.16.xlsx (backup for Figure 3)	
DX599				Data used by Leslie Sandberg Orne to generate Figure 4 to January 13, 2017 report: 6. CSO Analysis 12.22.16.xlsx (backup for Appendix E)	
DX600				Data used by Leslie Sandberg Orne to generate Figure 5 to January 13, 2017 report: 3. Promotion Cessation Analog Analysis 1.11.17.xlsx (backup for Figure 5)	
DX601				Data used by Leslie Sandberg Orne to generate Figure 6 to January 13, 2017 report: 4. Urology Salesforce Analyses 12.22.16.xlsx (backup for Figure 6)	
DX602				Data used by Leslie Sandberg Orne to generate Figure 7 to January 13, 2017 report: 3. Promotion Cessation Analog Analysis 1.11.17.xlsx (backup for Figure 7)	
DX603				INTENTIONALLY LEFT BLANK	
DX604				Data used by Leslie Sandberg Orne to generate Figure 9 to January 13, 2017 report: 7. Par Post Contract Inflection 12.22.16.xlsx (backup for Figure 9)	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX605				Data used by Leslie Sandberg Orne to generate Figure 10 to January 13, 2017 report: 8. TAP Structure Valuation Analysis 1.13.17.xlsx and 9. ICOS Structure Valuation Analysis 1.13.16.xlsx (backup for Figure 10)	
DX606	SLV134179	SLV134179	8/29/2001	Email from David Knocke to Jim Hynd, et al.	
DX607	SLV134180	SLV134210	8/28/2001	Document entitled AndroGel 2002 Business Plan	
DX608	SOLVAY 103763	SOLVAY 103796	8/12/2001	Document entitled AndroGel 2002 Business Plan	Hynd 05 (8/18/2011)
DX609	AGEL MDL 001-004301	AGEL MDL 001-004375	12/1/2002	Document entitled AndroGel (testosterone gel) 1% CIII 2003 Business Plan [Alt Bates SOLVAY 018589-18663]	
DX610	SLV000127	SLV000189		Document entitled AndroGel 2004 Business Plan	
DX611	SLV000190	SLV000239		Document entitled AndroGel 2005 Business Plan	
DX612	SLV301846	SLV301846	3/21/2007	Email from Leann Burns to Brian Hare	
DX613	SLV301847	SLV301896	3/21/2007	Document entitled AndroGel 2005 U.S. Business Plan - 1% CIII	
DX614	SLV526628	SLV526639	2/14/2007	Document entitled AndroGel 2007 Business Plan (to StratX)	
DX615	SLV000301	SLV000316	10/00/2007	Document entitled AndroGel 2007 Business Plan (brand team)	
DX616	AGEL-MDL-019-004250	AGEL-MDL-019-004281	10/9/2007	Document entitled AndroGel 2008 Business Plan	
DX617	AGEL-MDL-008-015421	AGEL-MDL-008-015469	9/10/2008	PowerPoint entitled AndroGel 2009 Business Plan	
DX618	AGEL-MDL-015-005627	AGEL-MDL-015-005675	9/10/2008	PowerPoint entitled AndroGel 2009 Business Plan	
DX619	ABBVIE-AGEL00609090	ABBVIE-AGEL00609090	7/6/2010	Email from Frank Jaeger to Sara Lehr	
DX620	ABBVIE-AGEL00609091	ABBVIE-AGEL00609161	6/28/2010	Document entitled AndroGel 2011 Strategic Business Plan, attachment to ABBVIE-AGEL00609090	
DX621				Photograph	Mink 33 (10/2/2015)
DX622				Photograph	Mink 34 (10/2/2015)
DX623				Photograph	Mink 35 (10/2/2015)
DX624	PADD-MDL-00012939	PADD-MDL-00012942	6/15/2011	Email from Gary Jossart to Bill Mink	Mink 47 (10/2/2015)
DX625	WTN0594293	WTN0594293		Watson testosterone API purchase history	Gwinn 9 (2/3/2016)
DX626	WTN0594330	WTN0594330		Watson testosterone API inventory spreadsheet	Petrie 36 (3/16/2016)
DX627	WTN0067745	WTN0067756	9/6/2006	Draft of Patent License Agreement between Unimed Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc.	
DX628				Exhibit 1 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX629				Exhibit 2 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX630				Exhibit 3 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX631				Exhibit 4 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX632				Exhibit 5a-5b to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX633				Exhibit 6a-6b to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX634				Exhibit 7 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX635				Exhibit 8a-8b to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX636				Exhibit 9a-9b to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX637				Exhibit 10 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX638				Exhibit 11 to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX639				Exhibit 12a-12b to the January 13, 2017 expert report Pierre Y. Cremieux, Ph.D.	
DX640				Chart and figure on page 63 to the January 13, 2017 expert report of Elizabeth C. Lindsey	
DX641				Chart on page 64 to the January 13, 2017 expert report of Elizabeth C. Lindsey	
DX642				Chart on page 65 to the January 13, 2017 expert report of Elizabeth C. Lindsey	
DX643				Figure 1 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX644				Figure 2 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX645				Figure 3 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX646				Figure 4 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX647				Figure 5 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX648				Figure 6 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX649				Figure 7 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX650				Figure 8 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX651				Figure 9 to January 13, 2017 expert report of Leslie Sandberg Orne	
DX652				Figure 10 to January 13, 2017 expert report of Leslie Sandberg Orne	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX653	SLV477043	SLV477121	8/24/2006	Email from Maury Mechanick to Joseph Mahoney; James Ferguson re: White & Case Comments on Draft Settlement and License, attaching Draft Settlement and Release Agreement, and Patent License Agreement	
DX654	PAR-MDL-00096659	PAR-MDL-00096660	8/15/2008	Email from David Elvin to Veronica Lubatkin, et al. re: July 2008 Sales and Margin - Generics vs. LE.xls, attaching spreadsheet entitled, "Par Pharmaceutical Net Sales and Gross Margin Analysis for July 2008 Actual vs. July 2008 LE"	Green 24
DX655	MEI_ANDRO 00032300B	MEI_ANDRO 00032300B	2010-2015	Meijer Androgel Purchase Data September 2010 to February 2015	
DX656	MEI_ANDRO 00000002	MEI_ANDRO 00000002	2005-2010	Meijer Androgel Purchase Data from December 2005 to August 2010	
DX657	MEI_ANDRO 00000003	MEI_ANDRO 00000004	10/4/2002	Agreement for Assignment of Claims between Meijer and Kerr assignment agreement	
DX658	ABBVIE-AGEL00913051	ABBVIE-AGEL00913051	2011-2015	Androgel Indirect Sales from April 1, 2011 to March 10, 2015	
DX659	ABBVIE-AGEL00913052	ABBVIE-AGEL00913052	2011	Rebates Androgel Data 2011 Q1	
DX660	ABBVIE-AGEL00913053	ABBVIE-AGEL00913053	2011	Rebates Androgel Data 2011 Q2	
DX661	ABBVIE-AGEL00913054	ABBVIE-AGEL00913054	2011	Rebates Androgel Data 2011 Q3	
DX662	ABBVIE-AGEL00913055	ABBVIE-AGEL00913055	2011	Rebates Androgel Data 2011 Q4	
DX663	ABBVIE-AGEL00913056	ABBVIE-AGEL00913056	2012	Rebates Androgel Data 2012 Q1	
DX664	ABBVIE-AGEL00913057	ABBVIE-AGEL00913057	2012	Rebates Androgel Data 2012 Q2	
DX665	ABBVIE-AGEL00913058	ABBVIE-AGEL00913058	2012	Rebates Androgel Data 2012 Q3	
DX666	ABBVIE-AGEL00913059	ABBVIE-AGEL00913059	2012	Rebates Androgel Data 2012 Q4	
DX667	ABBVIE-AGEL00913060	ABBVIE-AGEL00913060	2013	Rebates Androgel Data 2013 Q1	
DX668	ABBVIE-AGEL00913061	ABBVIE-AGEL00913061	2013	Rebates Androgel Data 2013 Q2	
DX669	ABBVIE-AGEL00913062	ABBVIE-AGEL00913062	2013	Rebates Androgel Data 2013 Q3	
DX670	ABBVIE-AGEL00913063	ABBVIE-AGEL00913063	2013	Rebates Androgel Data 2013 Q4	
DX671	ABBVIE-AGEL00913064	ABBVIE-AGEL00913064	2014	Rebates Androgel Data 2014 Q1	
DX672	ABBVIE-AGEL00913065	ABBVIE-AGEL00913065	2014	Rebates Androgel Data 2014 Q2	
DX673	ABBVIE-AGEL00913066	ABBVIE-AGEL00913066	2014	Rebates Androgel Data 2014 Q3	
DX674	ABBVIE-AGEL00913067	ABBVIE-AGEL00913067	2014	Rebates Androgel Data 2014 Q4	
DX675	ABBVIE-AGEL00913068	ABBVIE-AGEL00913068	2015	Rebates Androgel Data 2015 Q1	
DX676	ABBVIE-AGEL03267050	ABBVIE-AGEL03267050	3/11/2015 - 12/31/2015	Androgel Indirect Sales from March 11, 2015 to December 31, 2015	
DX677	ABBVIE-AGEL03267096	ABBVIE-AGEL03267096	2015	Rebates Androgel Data 2015 Q2 as of January 13, 2016	
DX678	ABBVIE-AGEL03267097	ABBVIE-AGEL03267097	2015	Rebates Androgel Data 2015 Q3 as of January 13, 2016	
DX679	ABBVIE-AGEL03267098	ABBVIE-AGEL03267098	2015	Rebates Androgel Data 2015 Q4 as of January 13, 2016	
DX680	ABBVIE-AGEL03268523	ABBVIE-AGEL03268523	2011-2016	Androgel Direct Sales from April 1, 2011 to January 12, 2016	
DX681	AGEL-MDL-020-000001	AGEL-MDL-020-000001		Manufacturer Data File	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX682	AGEL-MDL-020-000007	AGEL-MDL-020-000007	2006	Direct Sales Data 2006	
DX683	AGEL-MDL-020-000008	AGEL-MDL-020-000008	2007	Direct Sales Data 2007	
DX684	AGEL-MDL-020-000009	AGEL-MDL-020-000009	2008	Direct Sales Data 2008	
DX685	AGEL-MDL-020-000010	AGEL-MDL-020-000010	2009	Direct Sales Data 2009	
DX686	AGEL-MDL-020-000011	AGEL-MDL-020-000011	2010	Direct Sales Data 2010	
DX687	AGEL-MDL-020-000012	AGEL-MDL-020-000012	2011	Direct Sales Data 2011	
DX688	AGEL-MDL-020-000015	AGEL-MDL-020-000015	2006	Indirect Sales Data 2006	
DX689	AGEL-MDL-020-000016	AGEL-MDL-020-000016	2007	Indirect Sales Data 2007	
DX690	AGEL-MDL-020-000017	AGEL-MDL-020-000017	2008	Indirect Sales Data 2008	
DX691	AGEL-MDL-020-000018	AGEL-MDL-020-000018	2009	Indirect Sales Data 2009	
DX692	AGEL-MDL-020-000019	AGEL-MDL-020-000019	2010	Indirect Sales Data 2010	
DX693	AGEL-MDL-020-000020	AGEL-MDL-020-000020	2011	Indirect Sales Data 2011	
DX694	AGEL-MDL-020-000936	AGEL-MDL-020-000936		Indirect Sales Data	
DX695	AGEL-MDL-020-003832	AGEL-MDL-020-003832		Sales Data	
DX696	AGEL-MDL-BUR-000007	AGEL-MDL-BUR-000007		Manufacturer Data File	
DX697	PAR-MDL-00218627	PAR-MDL-00218627		Indirect Sales and Rebates Paid Data	
DX698	PAR-MDL-00218628	PAR-MDL-00218628		Direct Sales Data	
DX699	PRGO-00000331	PRGO-00000331		Perrigo Sales Data	
DX700	PRGO-00000332	PRGO-00000332		Perrigo Sales Data	
DX701	WTN0594329	WTN0594329		Actavis Generic AndroGel Sales	
DX702	WTN0594331	WTN0594331	2015	Testosterone GTN Payments 2015	
DX703	SLV442268	SLV442268	5/11/2006	Email from J. Janco to K. Rose, et al. re: 2007 5YP AndroGel Assumptions 051006	
DX704	SLV549559	SLV549563	4/24/2006	Watson and Solvay: A Strategic Fit in Urology	
DX705			5/4/2015	Direct Purchaser Class Plaintiffs' Objections and Responses to Defendant Abbvie Products LLC's First Set of Interrogatories to All Plaintiffs (Nos. 1-16)	
DX706			6/29/2015	Direct Purchaser Class Plaintiffs' Objections and Responses to Defendant Abbvie Products LLC's Second Set of Interrogatories to All Plaintiffs (No. 17)	
DX707			7/6/2015	Direct Purchaser Class Plaintiffs' Objections and Responses to Defendant Abbvie Products LLC's Third Set of Interrogatories to All Plaintiffs (No. 18)	
DX708			7/21/2015	Direct Purchaser Class Plaintiffs Rochester Drug Cooperative, Inc. and Louisiana Wholesale Drug Co., Inc.'s Supplemental Objections and Responses to Defendant Abbvie Products LLC's Second Set of Interrogatories to All Plaintiffs (No. 17)	
DX709			8/27/2015	Direct Purchaser Class Plaintiffs' Supplemental Objections and Responses to Defendant Abbvie Products LLC's First Set of Interrogatories to All Plaintiffs (Nos. 2, 3, 6-10)	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX710			10/16/2015	Direct Purchaser Class Plaintiffs' Second Supplemental Objections and Responses to Defendant Abbvie Products LLC's First Set of Interrogatories to All Plaintiffs (Nos. 2, 3, 6-10)	
DX711			11/23/2015	Direct Purchaser Class Plaintiffs' Third Supplemental Objections and Responses to Defendant Abbvie Products LLC's First Set of Interrogatories to All Plaintiffs (Nos. 2, 3, 6-10)	
DX712			1/19/2016	Direct Purchaser Class Plaintiffs' Objections and Responses to Defendant Abbvie Products LLC's Fourth Set of Interrogatories to All Plaintiffs (Nos. 19-24)	
DX713			2/18/2016	Direct Purchaser Class Plaintiffs' Supplemental Objections and Responses to Defendant Abbvie Products LLC's Fourth Set of Interrogatories to All Plaintiffs (No. 22)	
DX714			9/2/2016	Direct Purchaser Class Plaintiffs' Supplemental Objections and Responses to Defendant Abbvie Products LLC's First, Second and Fourth Set of Interrogatories to All Plaintiffs (Nos. 2, 3, 6-8, 17, 19-21)	
DX715	SLV041162	SLV041164	9/13/2006	Solvay Press Release - Unimed Pharmaceuticals, Inc. Settles AndroGel Litigation with Watson Pharmaceuticals, Inc. and Paddock Laboratories/Par Pharmaceutical Companies, Inc.	Govt Ex. 144
DX716	BNS0003917	BNS0003920	9/26/2006	Reciprocal Confidentiality Agreement between Besins International US, Inc. and Paddock Laboratories, Inc.	Govt Ex. 1020
DX717	PAR345027	PAR345027	6/13/2006	Email from Joseph Todisco to Paul Campanelli re Androgel Copromote Model	Todisco 3023(a)
DX718				Spreadsheet - Solvay Copromote Proposal	Todisco 3023(b)
DX719				Spreadsheet - Androgel IMS	Todisco 3023(c)
DX720	PAR345041	PAR345041	6/22/2006	Email from Joseph Todisco to Paul Campanelli re Solvay Copromotion Proposal	Todisco 3024(a)
DX721				Spreadsheet - Solvay Copromote Proposal	Todisco 3024(b)
DX722				Spreadsheet - Solvay Copromote Proposal - Alt	Todisco 3024(c)
DX723				Spreadsheet - Androgel IMS	Todisco 3024(d)
DX724	PAR343813	PAR343813	1/3/2006	Email from Paul Campanelli to D. Buchen re Androgel	Campanelli 15 (7/1/2011)
DX725	PAR343633	PAR343635	4/17/2006	Email from Ed Maloney to Paul Campanelli re Georgia	Campanelli 3005 (1/16/2008)
DX726	PAR-MDL-00031355	PAR-MDL-00031357	12/00/2007	Draft Unanimous Written Consent of the Par-Solvay AndroGel Joint Commercial Committee ("JCC") dated as of December_, 2007	MacPhee 27 (3/18/2016)
DX727	PAR063219	PAR334694	9/13/2006	Email from John MacPhee to Nefertiti Greene, et al. re Presentation (with attachment)	MacPhee 35 (3/18/2016)
DX728	PAR-MDL-00008643	PAR-MDL-00008645	6/20/2007	Email from Leslie Koby to Nefertiti Greene re Follow up minutes (with attachment)	MacPhee 36 (3/18/2016)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX729	BNS0004106	BNS0004109	11/7/2006	Email from Daniel De Grande to B. Mink and Flo Gilson re Preliminary technology transfer activity list (with attachment)	
DX730	PADD038236	PADD038238	11/8/2006	Email from Ed Maloney to Maureen Rath, et al. re Preliminary technology transfer activity list	Bua 15 (4/20/2016)
DX731	PAR338138	PAR338140	1/18/2007	Email from Nefertiti Greene to John MacPhee re Summary of Androgel Call Panel: Updated Version 11/16/07	Greene 19 (9/2/2015)
DX732	PAR-MDL-00029299	PAR-MDL-00029317	11/28/2007	Email from Carmen Bowen to John MacPhee re Jcc minutes Draft (with attachments)	Greene 20 (9/2/2015)
DX733	PAR216097	PAR216097	1/26/2007	Email from Leslie Koby to Terry Kirste re Contest and follow up	Greene 22 (9/2/2015)
DX734	PAR-MDL-00037832	PAR-MDL-00037832	2/27/2008	Email from Carmen Bowen to Darren Willoughby re Remit Payment to Solvay	Greene 23 (9/2/2015)
DX735	PAR-MDL-00096659	PAR-MDL-00096660	8/15/2008	Email from David Elvin to Veronica Lubatkin, et al. re July 2008 Sales and Martin - Generic vs. LE.xls (with attachment)	Greene 24 (9/2/2015)
DX736	PAR-MDL-00020397	PAR-MDL-00020399	10/10/2007	Email from Nefertiti Greene to Terry Kirste re 2008 Targeting Strategy.ppt (with attachment)	Greene 25 (9/2/2015)
DX737	PAR-MDL-00023703	PAR-MDL-00023705	11/13/2007	Email from John MacPhee to Nefertiti Greene re JCC Draft Slides	Greene 27 (9/2/2015)
DX738	PAR-MDL-00027884	PAR-MDL-00027884	11/16/2007	Email from Terry Kirste to Nefertiti Greene and Carmen Bowen re October 2007 Call Data	Greene 28 (9/2/2015)
DX739	RA-ANDRO-0000251	RA-ANDRO-0000309	10/26/2009	Email from Paul R Zabroske to April Hopper re Quarterly formulary update for web (with attachments)	McMahon 17 (02/24/2012)
DX740	RA-ANDRO-0000312	RA-ANDRO-0000371	11/16/2010	Email from April Hopper to Paul R Zabroske re Quarterly update to RAHS formulary (with attachment)	McMahon 18 (02/24/2012)
DX741	RA-ANDRO-0001286	RA-ANDRO-0001346	5/19/2011	Email from April Hopper to Karin Bell (with attachment)	McMahon 19 (02/24/2012)
DX742	RA-ANDRO-0000195	RA-ANDRO-0000199	7/30/2008	Email from Doug Zeiner to Owen P. McMahon re MI Pharmacists (with attachment)	McMahon 21 (02/24/2012)
DX743	PADD-MDL-00006362	PADD-MDL-00006362	6/13/2008	Email from Ed Maloney to Bill Mink re Solvay equipment	Mink 13 (10/2/2015)
DX744	PADD002118	PADD002119	9/30/2005	Meeting Notes from Janine Kelley to Pete Zeleny re Testosterone Gel	Mink 28 (10/2/2015)
DX745	PADD-MDL-00004258	PADD-MDL-00004261	4/1/2008	Email from Patrick Kaczaral to Oliver Raux re Transfer of Testosterone Release Rate Method to Montrouge	Mink 29 (10/2/2015)
DX746	PADD-MDL-00004288	PADD-MDL-00004290	4/3/2008	Email from Oliver Raux to Patrick Kaczaral et al. re IPM Method Transfer - Next Steps	Mink 30 (10/2/2015)
DX747	PADD-MDL-00002385	PADD-MDL-00002373	11/27/2007	Email from Lincy Michael to Neta Nelson et al. re List of documents needed for filing	Mink 31 (10/2/2015)
DX748	PADD-MDL-00000759	PADD-MDL-00000760	5/22/2007	Email from Matthew Zrebiec to Bill Mink et al. re Testosterone Gel Project	Mink 36 (10/2/2015)
DX749	PADD-MDL-00000815	PADD-MDL-00000816	6/14/2007	Email from Benoit Laurent to Bill Mink et al. re Techtransfer for Processing	Mink 37 (10/2/2015)

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX750	PADD-MDL-00008494	PADD-MDL-00008495	3/25/2009	Email from Patrick Kaczal to Hanspeter Dietschi re More Information regarding the Paddock equipment purchase (with attachment)	Mink 40 (10/2/2015)
DX751	PADD-MDL-00008104	PADD-MDL-00008106	1/4/2009	Email from Bill Mink to Ed Maloney et al. re Ceron Back up Manufacturing Plan (with attachment)	Mink 44 (10/2/2015)
DX752	PADD-MDL-00008337	PADD-MDL-00008339	2/24/2009	Email from Donald Pirkel to Ed Maloney re Creon Packaging Update	Mink 45 (10/2/2015)
DX753	WTN00291970	WTN00291976	1/27/2006	Letter from Gary Buehler to Christine M. Woods	Petrie 3 (03/16/2016)
DX754	WTN0093257	WTN0093260	3/23/2006	Proprietary R&D Meeting Minutes	Petrie 17 (03/16/2016)
DX755	WTN0521977	WTN0521983	7/9/2010	Generic Operations Meeting Minutes	Petrie 34 (03/16/2016)
DX756	PAR-MDL-00184579	PAR-MDL-00184580	1/28/2009	Email from Nefertiti Greene to John MacPhee and Barry Gilman re Strativa 2008 Call Plan performance	Greene 29 (9/2/2015)
DX757	PAR-MDL-00048210	PAR-MDL-00048211	9/30/2008	Email from John MacPhee to Nefertiti Greene, et al. re Board presentaiton (with attachment)	Greene 33 (9/2/2015)
DX758	PAR-MDL-00051028	PAR-MDL-00051028	12/10/2008	Email from Nefertiti Greene to John MacPhee re thought	Greene 34 (9/2/2015)
DX759	PAR-MDL-00189783	PAR-MDL-00189783	11/19/2010	Par Notice to Terminate Par-Abbott Co-Promotion Agreement	Greene 35 (9/2/2015)
DX760	SLV148636	SLV148649	9/28/2006	Presentation - Initial Working Session: Solvay & Par Pharmaceuticals	Amyot 16 (4/29/2015)
DX761	PADD001065	PADD001065	11/8/2006	Email from Bill Mink to Ed Maloney, et al. re Preliminary technology transfer activity list (with attachment)	
DX762	PADD002957	PADD002959	6/2/2003	From Wm Peter Rickman to Patrick L. Johnson re Reciept for Abbreviated New Drug Application	
DX763	PADD022545	PADD022546	2/14/2007	Email from Bill Mink to Ed Maloney et al. re T-gel conference call 2-14-07 (with attachment)	
DX764	PADD-MDL-00000917	PADD-MDL-00000918	7/9/2007	Email from Mary Beth Erstad to Jim Schwier re Agel presentations (with attachment)	
DX765	PADD-MDL-00002560	PADD-MDL-00002561	3/22/2007	Response to the audit performed by Solvay-Besins at Paddock Laboratories, Inc. January 9-10, 2007	
DX766	PADD-MDL-00012959	PADD-MDL-00012961	6/15/2011	Email from James Bueck to Gary Jossart re Testosterone Gel-ANDA 076744	
DX767	PADD-MDL-00016576	PADD-MDL-00016605	10/8/2003	Product Development, Manufacturing and Supply Agreement by and between Paddock Laboratories Inc and Par Pharmaceutical	
DX768	PADD-MDL-00018900	PADD-MDL-00018903	9/13/2006	Scott Tarriff to Ed Maloney re Supply Agreement Rights	
DX769	PAR144068	PAR144072	6/29/2005	Calendar Entry Meeting re GTx, Inc. - Fareston Acquisition/Co-Promote for 06/29/2005 (with attachments)	
DX770	PAR144180	PAR144183	7/6/2005	Email from Paul Campanelli to Joseph Todisco re Nascobal	
DX771	PAR266173	PAR266176	9/29/2003	Email from Paul Campanelli to Mike Graves re Summary of Teleconference	
DX772	PAR268339	PAR268339	9/10/2003	Email from Paul Campanelli to Scott Tarriff re AAI/Androgel	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX773	PAR343592	PAR343592	10/24/2005	Email from Ed Maloney to Paul Campanelli re Contact with Solvay	
DX774	PAR343603	PAR343606	10/30/2005	Email from Ed Maloney to Paul Campanelli re AWP and WAc	
DX775	PAR344354	PAR344358	8/21/2006	Email from Paul Campanelli to Peter Edwards re Teleconference Calls with Par on Tuesday, August 22 and Wednesday, August 23	
DX776	PAR455665	PAR455665	9/28/2005	Materials from Meeting with Sheldon Bradshaw and OGD	
DX777	PAR455916	PAR455916	5/31/2005	Memorandum from Scott Tarriff to Board of Directors re Authorized Generics	
DX778	PAR461807	PAR461821	9/13/2006	Patent License Agreement (Execution Copy)	
DX779	PAR-MDL-00000015	PAR-MDL-00000018	10/27/2004	Gary Buehler to Todd M. Delehant, PhD. Re Tentative Approval of ANDA	
DX780	PAR-MDL-00000204	PAR-MDL-00000208	5/23/2007	Gary Buehler to Julie Szozda re Approval of ANDA	
DX781	PAR-MDL-00000529	PAR-MDL-00000589	7/11/2010	Amendment to the Prior Approval Supplement RE: ANDA 076744-Testosterone Gel 1% CIII	
DX782	PAR-MDL-00003321	PAR-MDL-00003324	3/30/2007	Email from Nefertiti Greene to Paul Campanelli et al. re Androgel Details	
DX783	PAR-MDL-00179953	PAR-MDL-00179963	9/13/2006	Asset Purchase Agreement (Execution Copy)	
DX784	PAR-MDL-00188288	PAR-MDL-00188289	1/10/2010	Email from Nefertiti Greene to Katherine Burns re Slides (with attachments)	
DX785	SLV585172	SLV585174	4/30/2004	Alternative Manufacturing Site - AndroGel Memorandum from BESINS	
DX786	WTN0096761	WTN0096763	7/7/2003	FDA Letter to Watson	
DX787	WTN00291967	WTN00291969	10/31/2006	Letter from Ernest Lenge, Ph.D. to Gary Buehler, R.Ph re Documentation of Litigation/Settlement Outcome for ANDA No. 76-767 1% Testosterone Gel	
DX788			5/4/2015	Plaintiffs' Response to Defendant Abbvie Products LLC's First Set of Interrogatories to All Plaintiffs	
DX789			8/27/2015	CVS and Rite Aid's Supplemental Responses and Objections to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	
DX790			8/27/2015	Walgreen Plaintiffs' Supplemental Objections and Responses to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	
DX791			10/16/2015	CVS and Rite Aid's Second Supplemental Responses and Objections to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	
DX792			10/16/2015	Walgreen Plaintiffs' Second Supplemental Responses and Objections to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX793			11/23/2015	CVS and Rite Aid's Third Supplemental Responses and Objections to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	
DX794			11/23/2015	Walgreen Plaintiffs' Third Supplemental Responses and Objections to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 9, and 10	
DX795			1/19/2016	CVS and Rite Aid's Responses and Objections to Defendant Abbvie Products LLC's Fourth Set of Interrogatories to Private Plaintiffs	
DX796			1/19/2016	Plaintiffs' Response to Defendant Abbvie Products LLC's Fourth Set of Interrogatories to Private Plaintiffs	
DX797			9/2/2016	CVS and Rite Aid's Supplemental Responses to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 17, 19, 20, and 21	
DX798			9/2/2016	Retailer Plaintiffs' Supplemental Responses to Defendant Abbvie Products LLC's Interrogatory Nos. 2, 3, 6, 7, 8, 17, 19, 20, and 21	
DX799	PAR456785	PAR456829	9/21/2006	Email from Nefertiti Greene to Thomas Fogarty and John MacPhee re Executed Documents (with attachment)	Greene 01 (9/2/2015)
DX800	PAR339969	PAR339969	1/23/2007	Email from Leslie Koby to Vincent Amyot re AndroGel target addresses	Greene 21 (9/2/2015)
DX801	PADD016686	PADD016687	9/2/2004	Email from Mary Beth Erstad to Ed Maloney re Testosterone Gel Forecast	
DX802	PADD016688	PADD016688	8/20/2004	Spreadsheet: Testosterone Gel Forecast (attachment to Email from Mary Beth Erstad to Ed Maloney, PADD016686-87)	
DX803	PAR 00202	PAR 00218		Document Entitled Testosterone Gel Executive Summary	Campanelli 21 (7/1/2011)
DX804	WTN0225722	WTN0225923	12/30/2003	Letter from Watson Laboratories, Inc. to FDA. re: Amendment to ANDA 76-737	
DX805	WTN0096761	WTN0096763	7/7/2003	Letter from FDA to Watson Laboratories, Inc.	
DX806	WTN0521977	WTN0521983	7/9/2010	Generic Ops Meeting Minutes	
DX807	WTN0411504	WTN0411504	8/12/2010	Email from J Gwinn to E. Brannan re: Testosterone API	
DX808	WTN0333572	WTN0333575	2/28/2013	Amendment to Prior Approval Supplement	
DX809	WTN0441656	WTN0441668	2/28/2013	Notice of Paragraph IV Certification	
DX810	WTN0379855	WTN0379857	6/10/2010	Letter from FDA to Watson Laboratories, Inc. re: PAS	
DX811	WTN0334538	WTN0334545	9/20/2013	Letter from Watson Laboratories, Inc. to FDA.	
DX812	WTN0367021	WTN0367024	9/24/2014	Letter from FDA to Watson Laboratories, Inc. re: PAS	
DX813	WTN0410317	WTN0410318	3/9/2015	Letter from FDA to Watson Laboratories, Inc. re: PAS	
DX814	WTN0387406	WTN0387408	8/7/2014	Letter from FDA to Watson Laboratories, Inc. re: PAS	
DX815	WTN0591630	WTN0591630	4/7/2015	Letter from Actavis Laboratories UT, Inc. to FDA	
DX816	WTN0591651	WTN0591659	5/22/2015	Letter from Actavis Laboratories UT, Inc. to FDA re: PAS	
DX817	WTN0594278	WTN0594289	11/5/2015	Letter from FDA to Actavis Laboratories UT, Inc. re: PAS	

DEFENDANTS' TRIAL EXHIBIT LIST

November 15, 2019

DX NO.	BEGBATES	ENDBATES	DATE	DESCRIPTION	ALSO REFERENCED AS
DX818	WTN0591677	WTN0591679	5/27/2015	Letter from Actavis Laboratories UT, Inc. to FDA re: CBE Supplement	
DX819	WTN0594290	WTN0594292	10/28/2015	Letter from FDA to Actavis Laboratories UT, Inc. re: CBE Supplement	
DX820	WTN0311794	WTN0311796	5/25/2005	Watson Project Cross-Functional Team Meeting Minutes	
DX821	WTN0594852	WTN0594854	3/29/2010	Letter from FDA to Watson Laboratories, Inc. re: PAS	
DX822			11/1/1995	MAPP 5240.1 Requests for Expedited Review of Supplements to Approved ANDAs and AADAs	Petrie 2 (3/16/2016)
DX823	WTN0404230	WTN0404236	9/24/2014	Resubmission - Minor, Complete Response Amendment, Chemistry	Petrie 14 (3/16/2016)
DX824	WTN0313833	WTN0313929	4/21/2006	Proprietary R&D Meeting Minutes - Draft with cover e-mail from Tom Eckstein	Petrie 30 (3/16/2016)
DX825	WTN0328635	WTN0328647	9/2/2006	2006-2007 Generic Product Launch Summary with cover e-mail from Fred Weihmuller	Petrie 31 (3/16/2016)
DX826	PADD002924	PADD002925	8/28/2003	Email from Mary Beth Erstad to Joann Zilka et al. re AndroGel	
DX827	PAR 008609	PAR 008623	8/9/2005	Document Entitled Testosterone Gel 1% Executive Summary	
DX828	PAR 008645	PAR 008659	8/29/2005	Document Entitled Testosterone Gel 1% Executive Summary	
DX829	PAR 008660	PAR 008674	10/3/2005	Document Entitled Testosterone Gel 1% Executive Summary	
DX830	PAR464134	PAR464152		Spreadsheet Entitled Testosterone Gel Executive Summary	
DX831	PAR-MDL-00187760	PAR-MDL-00187761	10/14/2009	Email from John MacPhee to Nefertiti Greene re Strativa Operating Plan	
DX832	PAR-MDL-00189776	PAR-MDL-00189781	11/18/2010	Email from Marian Gustafson to Erin Zaccaro et al re Contract Circulation: Abbott Laboratories (Solvay) Androgel CoPromote Amendment (with attachment)	MacPhee 32 (3/18/2016)